Note: Descriptions are shown in the official language in which they were submitted.
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
PHARMACEUTICAL DOSAGE FORMS COMPR[SING A LOW-SOLUBILITY DRUG AND A
POLYMER
Background
The present invention relates to pharmaceutical dosage forms comprising a low-
solubility drug and a polymer.
It is known in the art that a low-solubility drug may be combined with a
polymer to
increase the concentration of dissolved drug in an aqueous use environment
relative to a
composition that does not contain the polymer. For example, Curatolo et al.,
US Patent No.
6,548,555 BI, disclose compositions comprising a basic drug admixed with a
polymer
selected from the group consisting of hydroxypropylmethyl cellulose acetate
succinate
(HPMCAS), cellulose acetate trimellitate (CAT), cellulose acetate phthatlate
(CAP),
hydroxypropyl cellulose acetate phthalate (HPCAP), hydroxypropylmethyl
cellulose acetate
phthalate (HPMCAP), and methyl cellulose acetate phthatlate (MCAP). The basic
drug, when
administered to a gastric use environment, initially dissolves 'to a high
concentration. This
high concentration is sustained by the presence of the polymer when the drug
enters a higher
pH intestinal use environment.
Curatolo, et al., US published patent application 2002/0006443A1, disclose
mixtures
of solubility-improved forms of drugs and a polymer. The solubility-improved
form may be
crystalline, such as a high-solubility salt or polymorph, that provides, at
least temporarily,
enhanced aqueous solubility relative to the lowest-energy crystalline drug
form.
Curatolo, et al., US published patent application 2003/0072801A1, disclose
several
solubilized drug forms combined with various polymers. The application
discloses, among
other things, such solubilized drug forms as nanoparticles and cyclodextrin
complexes
combined with polymers.
While not wishing to be bound by a particular theory, it is believed that the
polymer,
when combined with a solubilized drug, generally does not have the capacity to
greatly
solubilize insoluble drugs (that is, to increase the equilibrium solubility of
free drug). Instead,
it is believed the polymer primarily acts to slow the rate of precipitation or
crystallization of the
drug after the drug is initially dissolved. The presence of the polymer(s)
thus allows the
initially increased or enhanced concentration provided by the solubility-
improved form of the
drug to be at least partially maintained for at least a few minutes and, in
some cases, for
many hours. In addition, in cases where dissolution of the solubility-improved
form of the
drug is slow and precipitation of the low-solubility drug form, in the absence
of the polymer, is
fast, the presence of the polymer may result in the maximum concentration of
drug observed
being substantially higher than that observed in the absence of the polymer.
One possible mechanism for improving the dissolved drug concentration involves
the
association of the polymer and dissolved drug to form "polymer/drug
assemblies." Such
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-2-
assemblies may constitute various forms, including polymeric micelles, high-
energy polymer-
drug aggregates ranging in size from a few nanometers to 1000 nanometers,
polymer-
stabilized drug colloids or polymer/drug complexes. An alternative view is
that as dissolved
drug begins to precipitate or crystallize from solution (e.g., as nucleation
begins) the polymer
adsorbs to these drug aggregates or nuclei, preventing, or at least retarding,
the nucleation or
crystal-growth process. In any case, the presence of the polymer serves to
enhance the
amount of drug that is dissolved or at least available for absorption. The
various
drug/polymer assemblies listed above are apparently quite labile and may
contribute to the
drug absorption process.
However, when the low-solubility drug and polymer are mixed together with
other
excipients to form a dosage form, the polymer and drug may become segregated
or diluted
relative to each other during manufacture of the dosage form. When the dosage
form is then
subsequently administered to an aqueous use environment, such as an in vitro
dissolution
test or the gastrointestinal tract of an animal, the drug and polymer may not
be immediately
adjacent to one another, which may impede the formation of polymer/drug
assemblies.
Alternatively, the dosage forms may provide variable performance due to
segregation of the
drug and polymer during manufacture. In addition, even when the polymer and
drug remain
uniformly mixed, during dissolution of the drug, the concentration of
dissolved drug near the
surface of the drug particles may exceed its equilibrium value and begin to
precipitate or
crystallize prior to encountering sufficient levels of dissolved polymer or
polymer-colloids to
inhibit such crystallization or inhibition.
Accordingly, it is desired to combine a low-solubility drug and precipitation-
inhibiting
polymer in a dosage form in a manner that facilitates reproducibly achieving
concentration-
enhancement of dissolved drug in a use environment, and/or provides or
sustains higher
concentrations of dissolved drug.
Summary of the Invention
In one aspect, a dosage form comprises a low-solubility drug and a
precipitation-
inhibiting polymer. The low-solubility drug is in a soiubility-improved form
and in the form of
particles at least partially coated with the precipitation-inhibiting polymer.
The dosage forms of the present invention ameliorate the problem of
variability in
performance by combining the drug and polymer together so that the drug and
polymer
remain in contact with each other during formation of the dosage form, and
later during
release of the drug from the dosage form. Since the polymer at least partially
coats the drug,
the drug and polymer remain in contact during formation of the dosage form.
Even as the
drug and polymer are combined with other excipients, such as binders,
diluents, disintegrants,
osmagents, or other such materials, nevertheless the drug and polymer are not
diluted
relative to each other during manufacture of the dosage form. Nor are the drug
and polymer
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-3-
segregated from one another due to inhomogeneities that may occur when
combining the
drug and excipients that make up the dosage form. Thus, regardless of the
amount of
additional excipients or the degree of homogeneity of the materials used to
form the dosage
form, the polymer and drug remain in contact in the finished dosage form. As a
consequence,
the drug and polymer are still in contact as the drug is released from the
dosage form into an
aqueous use environment. This is advantageous to achieving good performance,
since in the
absence of the polymer the drug that begins to dissolve after release will
soon begin to
precipitate. However, when the drug and polymer are in contact with one
another at the time
of release into the aqueous use environment, the drug and polymer can begin to
dissolve
together in close proximity. This facilitates the formation of polymer/drug
assemblies, or may
allow the polymer to adsorb to drug aggregates or nuclei, preventing, or at
least retarding, the
nucleation or crystal-growth process. In any case, the close proximity of the
polymer to the
drug at the time of release into the use environment serves to enhance the
amount of drug
that remains dissolved or at least available for absorption.
In addition, at least partial coating of the drug particles by the polymer can
retard the
dissolution of the drug until the polymer is at least first partially
dissolved. This is particularly
important when the polymer is slow to dissolve relative to the drug or when
the drug and
polymer may be, at least temporarily in an environment where the polymer is
relatively
insoluble compared to the drug. For example, when the polymer is relatively
insoluble at low
pH, such as an enteric polymer, coating of the drug by the polymer may prevent
or retard the
dissolution of drug until it reaches an environment where the pH is high
enough for the
polymer to swell, disperse, or dissolve.
The foregoing and other objectives, features, and advantages of the invention
will be
more readily understood upon consideration of the following detailed
description of the
invention.
Brief Description of the Drawings
FIG. 1 shows schematically in cross section polymer coated drug particles.
FIG. 2 shows schematically in cross section polymer coated particles
comprising drug
particles and polymer particles.
Detailed Description of the Invention
The dosage forms of the present invention comprise a low-solubility drug and a
precipitation-inhibiting polymer. The low-solubility drug is in the form of
particles at least
partially coated with the precipitation-inhibiting polymer. By "particles" is
meant, when the
drug is crystalline, individual crystals of the drug. When the drug is
amorphous, "particles"
refers to individual particles comprising drug in amorphous form. In general,
the particles may
range in size from about 0.1 pm to about 500 pm.
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-4-
By "at least partially coated" with a precipitation-inhibiting polymer means
that the
precipitation-inhibiting polymer partially coats at least a portion of the
surface of the drug
particles. The precipitation-inhibiting polymer may coat only a portion of the
drug particle, or
may fully coat or encapsulate the entire surface of the drug particle. For
example, FIG. 1
shows schematically a composition 10 comprising particles 12 of crystalline
drug with
precipitation-inhibiting polymer coating 14. Coated particle A has a portion
of the surface of
the crystalline drug 12 coated with the precipitation-inhibiting polymer 14.
Coated particle B
has the crystalline drug 12 completely coated or encapsulated with the
precipitation-inhibiting
polymer 14. Thus, the compositions may contain particles that are partially
coated with
precipitation-inhibiting polymer, may contain particles that are completely
coated, or may
contain a mixture of partially and completely coated particles. The drug
particles are coated
such that at least a portion of the surface of the drug particle is in direct
contact with the
precipitation-inhibiting polymer. The at least partially coated particles are
in contrast to a
simple dry physical mixture of drug and polymer particles wherein both the
drug and polymer
are mixed in particulate form and wherein the particles of each are physically
separate from
one another.
In another embodiment shown schematically in FIG. 2, a composition 20
comprises
drug particles 22, precipitation-inhibiting polymer coating 24, and additional
particles of
precipitation-inhibiting polymer 26. The precipitation-inhibiting polymers 24
and 26 may be
the same or different. In one preferred embodiment, the precipitation-
inhibiting polymers 24
and 26 are both hydroxypropylmethyl cellulose acetate succinate. This
embodiment has
particular utility when it is desired to have a' relatively high weight ratio
of polymer to drug
(e.g., a polymer to drug weight ratio of greater than about 0.5). The
efficiency of the coating
process used to coat the precipitation-inhibiting polymer onto the drug
particles is a function
of the amount of precipitation-inhibiting polymer that must be dissolved and
coated onto the
drug particles. In this embodiment, only a portion of the precipitation-
inhibiting polymer is
dissolved and coated, whereas the remainder is present as particles.
Nonetheless, the
resulting composition contains drug particles at least partially coated with
the precipitation-
inhibiting polymer, and also contain additional precipitation-inhibiting
polymer 26, all of which
are present in the composition 20.
The precipitation-inhibiting polymer coating and drug, while in contact with
one
another, are in separate phases. The drug particle, when a crystalline drug
form, remains
relatively pure drug, and retains its characteristic properties such as
melting point or glass
transition temperature. Thus, the polymer coated drug particles are in
contrast to molecular
dispersions or solid solutions of the drug in the polymer.
In addition, the drug particles may be either individually coated, or several
drug
particles may be coated with polymer and present in a single particle. For
example, returning
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-5-
to FIG. 1, particle B is an individually coated drug crystal, while particle C
consists of several
drug crystals 12 coated with precipitation-inhibiting polymer 14. In cases
where the drug
particles are quite small, there can be many drug particles within the polymer-
coated drug
particle. For example, a polymer coated drug particle having a diameter of
about 100 pm may
contain more than one million drug particles that have a diameter on the order
of 0.1 to 1 pm.
Thus, the compositions may contain individually coated drug particles, may
contain coated
particles containing several drug particles, or both. In those embodiments in
which the coated
particles contain several drug particles, it is preferred that the coated
particles remain small.
It is preferred that the coated drug particles remain smaller than about 500
pm in average
diameter. The particles may be smaller than about 100 pm, smaller than about
50 pm, or
even smaller than about 20 pm in average diameter. Thus, the polymer coated
drug particles
are free flowing particulates that may be mixed and/or blended with other
excipients to form a
dosage form.
The dosage form may also contain one or more excipients in addition to the
polymer
coated drug particles. The invention finds particular utility where the dosage
form contains an
additional excipient. The polymer and drug remain in contact with one another
and do not
become segregated or diluted due to the presence of the excipient in the
dosage form. The
excipient may be combined with the polymer coated particles in any fashion.
Thus, the drug
and excipient may be coated together with the polymer. Alternatively, the
excipient may be
mixed or blended with the polymer coated particles subsequent to coating of
the drug
particles with polymer.
While the dosage form comprises polymer coated drug particles, the dosage form
may also comprise drug that is not coated with a polymer. In addition, the
dosage form may
also comprise drug that is not in a solubility-improved form. For example,
where the dosage
form has an immediate release component and a sustained release component, the
drug in.
the sustained release component may be in the solubility-improved form and may
be at least
partially coated with the polymer, while the drug in the immediate release
component may be
the lowest solubility form without any polymer coating.
The Drug
The term "drug" is conventional, denoting a compound having beneficial
prophylactic
and/or therapeutic properties when administered to an animal, especially
humans. By "low-
solubility drug" is meant that the drug may be either "substantially water-
insoluble," which
means that the drug has a minimum aqueous solubility at any physiologically
relevant pH
(e.g., pH 1-8) of less than 0.01 mg/mL, "sparingly water-soluble," that is,
has an aqueous
solubility up to about I to 2 mg/mL, or even low to moderate aqueous-
solubility, having an
aqueous-solubility from about 1 mg/mL to as high as about 20 to 40 mg/mL. The
invention
finds greater utility as the solubility of the drug decreases. Thus,
compositions of the present
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-6-
invention are preferred for low-solubility drugs having a minimum solubility
of less than
mg/mL, more preferred for low-solubility drugs having a minimum solubility of
less than
I mg/mL, more preferred for low-solubility drugs having a minimum solubility
of less than
0.5 mg/mL, and even more preferred for low-solubility drugs having a minimum
solubility of
5 less than 0.1 mg/mL. In general, it may be said that the drug has a dose-to-
aqueous solubility
ratio greater than 10 mL, and more typically greater than 100 mL, where the
drug solubility
(mg/mL) is the minimum value observed in any physiologically relevant aqueous
solution
(e.g., those with pH values between 1 and 8) including USP simulated gastric
and intestinal
buffers, and dose is in mg. Thus, a dose-to-aqueous solubility ratio may be
calculated by
10 dividing the dose (in mg) by the solubility (in mg/mL).
Preferred classes of drugs include, but are not limited to, antihypertensives,
antianxiety agents, anticlotting agents, anticonvulsants, blood glucose-
lowering agents,
decongestants, antihistamines, antitussives, antineoplastics, beta blockers,
anti-
inflammatories, antipsychotic agents, cognitive enhancers, cholesterol-
reducing agents, anti-
atherosclerotic agents, antiobesity agents, autoimmune disorder agents, anti-
impotence
agents, antibacterial and antifungal agents, hypnotic agents, anti-
Parkinsonism agents, anti-
Alzheimer's disease agents, antibiotics, anti-depressants, antiviral agents,
glycogen
phosphorylase inhibitors, and cholesteryl ester transfer protein inhibitors.
Each named drug should be understood to include any pharmaceutically
acceptable
forms of the drug. By "pharmaceutically acceptable forms" is meant any
pharmaceutically
acceptable derivative or variation, including stereoisomers, stereoisomer
mixtures,
enantiomers, solvates, hydrates, isomorphs, polymorphs, neutral forms, salt
forms and
prodrugs. Specific examples of antihypertensives include prazosin, nifedipine,
amlodipine
besylate, trimazosin and doxazosin; specific examples of a blood glucose-
lowering agent are
glipizide and chlorpropamide; a specific example of an anti-impotence agent is
sildenafil and
sildenafil citrate; specific examples of antineoplastics include chlorambucil,
lomustine and
echinomycin; a specific example of an imidazole-type antineoplastic is
tubulazole; a specific
example of an anti-hypercholesterolemic is atorvastatin calcium; specific
examples of
anxiolytics include hydroxyzine hydrochloride and doxepin hydrochloride;
specific examples of
anti-inflammatory agents include betamethasone, prednisolone, aspirin,
piroxicam,
valdecoxib, carprofen, celecoxib, flurbiprofen and (+)-N-{4-[3-(4-
fluorophenoxy)phenoxy]-2-
cyclopenten-1-yl}-N-hyroxyurea; a specific example of a barbiturate is
phenobarbital; specific
examples of antivirals include acyclovir, nelfinavir, and virazole; specific
examples of
vitamins/nutritional agents include retinol and vitamin E; specific examples
of beta blockers
include timolol and nadolol; a specific example of an emetic is apomorphine;
specific
examples of a diuretic include chlorthalidone and spironolactone; a specific
example of an
anticoagulant is dicumarol; specific examples of cardiotonics include digoxin
and digitoxin;
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-7-
specific examples of androgens include 17-methyltestosterone and testosterone;
a specific
example of a mineral corticoid is desoxycorticosterone; a specific example of
a steroidal
hypnotic/anesthetic is alfaxalone; specific examples of anabolic agents
include
fluoxymesterone and methanstenolone; specific examples of antidepression
agents include
sulpiride, [3,6-d imethyl-2-(2,4,6-trimethyl-phenoxy)-pyrid in-4-yl]-(1 -ethyl
propyl)-am ine, 3,5-
dimethyl-4-(3'-pentoxy)-2-(2',4',6'-trimethylphenoxy)pyridine, pyroxidine,
fluoxetine,
paroxetine, venlafaxine and sertraline; specific examples of antibiotics
include carbenicillin
indanylsodium, bacampicillin hydrochloride, troleandomycin, doxycyline
hyclate, ampicillin
and penicillin G; specific examples of anti-infectives include benzalkonium
chloride and
chlorhexidine; specific examples of coronary vasodilators include
nitroglycerin and mioflazine;
a specific example of a hypnotic is etomidate; specific examples of carbonic
anhydrase
inhibitors include acetazolamide and chlorzolamide; specific examples of
antifungais include
econazole, terconazole, fluconazole, voriconazole, and griseofulvin; a
specific example of an
antiprotozoal is metronidazole; specific eXamples of antheimintic agents
include
thiabendazole and oxfendazole and morantel; specific examples of
antihistamines include
astemizole, levocabastine, cetirizine, decarboethoxyloratadine and
cinnarizine; specific
examples of antipsychotics include ziprasidone, olanzepine, thiothixene
hydrochloride,
fluspirilene, risperidone and penfluridole; specific examples of
gastrointestinal agents include
loperamide and cisapride; specific examples of serotonin antagonists include
ketanserin and
mianserin; a specific example of an anesthetic is lidocaine; a specific
example of a
hypoglycemic agent is acetohexamide; a specific example of an anti-emetic is
dimenhydrinate; a specific example of an antibacterial is cotrimoxazole; a
specific example of
a dopaminergic agent is L-DOPA; specific examples of anti-Alzheimer's Disease
agents are
THA and donepezil; a specific example of an anti-ulcer agent/H2 antagonist is
famotidine;
specific examples of sedative/hypnotic agents include chlordiazepoxide and
triazolam; a
specific example of a vasodilator is alprostadil; a specific example of a
plateiet,inhibitor is
prostacyclin; specific examples of ACE inhibitor/antihypertensive agents
include enalaprilic
acid and lisinopril; specific examples of tetracycline antibiotics include
oxytetracycline and
minocycline; specific examples of macrolide antibiotics include erythromycin,
clarithromycin,
and spiramycin; a specific example of an azalide antibiotic is azithromycin;
specific examples
of glycogen phosphorylase inhibitors include [R-(RS)]-5-chloro-N-[2-hydroxy-3-
{methoxymethylamino}-3-oxo-1-(phenylmethyl)propyl-1 H-indole-2-carboxamide and
5-chloro-
1 H-indole-2-carboxylic acid [(1 S)-benzyl-(2R)-hydroxy-3-((3R,4S)-dihydroxy-
pyrrolidin-1-yl-)-
3-oxypropyl]amide; and specific examples of cholesteryl ester transfer protein
(CETP)
inhibitors include [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-
amino]-2-ethyl-6-
trifluoromethyl-3,4-dihydro-2H-quinoline-l-carboxylic acid ethyl ester,
[2R,4S] 4-[acetyl-(3,5-bis-
trifluoromethyl-benzyl)-amino]-2-ethyl-6-trifluoromethyl-3,4-d ihydro-2H-
quinoline-l-carboxylic
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-8-
acid isopropyl ester, [2R, 4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-
methoxycarbonyl-amino]-2-
ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-l-carboxylic acid isopropyl
ester, (2R)-3-[[3-(4-
chloro-3-ethylphenoxy)phenyl] [[3-(1,1,2,2-
tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-
trifluoro-2-propanol, the drugs disclosed in commonly owned U.S. Patent
Application Serial
Nos. 09/918,127 and 10/066,091, both of which are incorporated herein by
reference in their
entireties for all purposes, and the drugs disclosed in the following patents
and published
applications: DE 19741400 Al; DE 19741399 Al; WO 9914215 Al; WO 9914174; DE
19709125 A1; DE 19704244 Al; DE 19704243 Al; EP 818448 Al; WO 9804528 A2; DE
19627431 Al; DE 19627430 Al; DE 19627419 Al; EP 796846 A1; DE 19832159; DE
818197;
DE 19741051; WO 9941237 Al; WO 9914204,A1; WO 9835937 Al; JP 11049743; WO
200018721; WO 200018723; WO 200018724; WO 200017164; WO 200017165; WO
200017166; EP 992496; and EP 987251, all of which are hereby incorporated by
reference in
their entireties for all purposes.
The low-solubility drug is in a solubility-improved form. The term "solubility-
improved
form" refers to a form of the drug alone that, when delivered to an in vivo
use environment
(such as, for example, the gastrointestinal tract of a mammal) or an in vitro
use environment
(such as distilled water, phosphate buffered saline or a Model Fasted Duodenal
solution
described below) provides, at least temporarily, a maximum concentration of
drug that is at
least 1.25-fold the equilibrium concentration provided by the lowest
solubility form of the drug
known, a faster dissolution rate of the drug, or both. For example, for a
basic drug, if the free
base form of the drug provides an equilibrium dissolved drug concentration of
10
micrograms/mi in an in vitro test solution, the solubility-improved form of
the drug would
provide a maximum dissolved drug concentration of at least 12.5 micrograms/mi.
Examples
of "solubility-improved forms" include but are not limited to: (1) a
crystalline highly soluble
form of the drug such as a salt; (2) a high-energy crystalline form of the
drug; (3) a hydrate or
solvate crystalline form of a drug; (4) an amorphous form of a drug (for a
drug that may exist
as either amorphous or crystalline); (5) drug particles having reduced or
small particle size;
(6) drug in semi-ordered from in which the drug may have properties that lie
between those of
a crystalline form of the drug and an amorphous form of the drug; and (7) drug
in a
cyclodextrin complex. the solubility improved form may comprise a mixture of
two or more of
such solubility-improved forms.
In one aspect of the invention, the solubility-improved form of the drug is
crystalline
and is a highly soluble salt form of the drug. As used herein, "highly soluble
salt form" means
that the drug is in a salt form that provides solubility improvement as
described below. The
drug can be any pharmaceutically acceptable salt form of a basic, acidic, or
zwitterionic drug
that meets this criteria. Examples of salt forms for basic drugs include the
chloride, bromide,
acetate, iodide, mesylate, phosphate, maleate, citrate, sulfate, tartrate,
lactate salts and the
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-9-
like. Examples of salt forms for acidic drugs include the sodium, calcium,
potassium, zinc,
magnesium, lithium, aluminum, meglumine, diethanolamine, benzathine, choline,
and
procaine salts and the like. These salts can also be used for zwitterionic
drugs.
An example of a drug having a crystalline highly soluble salt form is
ziprasidone.
Ziprasidone hydrochloride monohydrate has a solubility of about 10 pgA/mL
(expressed as
the free base) in water, whereas the free base form has a solubility of less
than about 0.2
pgA/mL under the same conditions. Thus, crystallinp ziprasidone hydrochloride
is a solubility-
improved form relative to the crystalline free base form of ziprasidone. When
dosed to a
buffered aqueous solution such as phosphate buffered saline at pH 6.5, the
crystalline
ziprasidone hydrochloride monohydrate dissolves such that it achieves a
maximum
concentration of about 0.4 to 1.2 pgA/mL. However, at equilibrium, the drug
crystallizes from
such solutions as the free base form such that the equilibrium solubility of
ziprasidone is
about 0.2 pgA/mL.
Alternatively, in another separate aspect of the invention, the drug exists in
a high-
energy crystalline form that has improved solubility relative to a low-energy
crystalline form. It
is known that some drugs may crystallize into one of several different crystal
forms. Such
crystal forms are often referred to as "polymorphs." As used herein, "a high-
energy crystalline
form" means that the drug is in a crystal form which provides solubility
improvement as
described below. An example of such a drug is the "Al" form of 5-chloro-1 H-
indole-2-
carboxylic acid [(1S)-benzyl-3-((3R,4S)-dihydroxypyrrolidin-l-yl)-(2R)-hydroxy-
3-oxpropyl]
amide, which has a solubility in phosphate buffered saline (PBS at pH 6.5) of
about
480 pg/mL while the "A2" form has a solubility in PBS of only 87 Ng/mL.
In yet another separate aspect of the invention, although the drug may be
capable of
existing in either the amorphous or crystalline form, in the composition it is
in the amorphous
form. Preferably, at least a major portion of the drug is amorphous. By
"amorphous" is meant
simply that the drug is in a non-crystalline state. As used herein, the term
"a major portion" of
means that at least 60 wt% of the drug in the composition is in the amorphous
form, rather
than the crystalline form. Preferably, the drug is substantially amorphous. As
used herein,
"substantially amorphous" means that the amount of drug in crystalline form
does not exceed
about 25 wt%. More preferably, the drug is "almost completely amorphous,"
meaning that the
amount of drug in the crystalline form does not exceed about 10 wt lo. Amounts
of crystalline
drug may be measured by Powder X-Ray Diffraction (PXRD), Scanning Electron
Microscope
(SEM) analysis, differential scanning calorimetry (DSC), or any other standard
quantitative
measurement. The drug in its amorphous form provides in at least an in vitro
test medium a
maximum concentration of the drug that is greater than the maximum
concentration of the
drug provided by the drug in crystalline form. An example of such a drug is 5-
chloro-1 H-
indole-2-carboxylic acid [(1S)-benzyl -3-((3R, 4S) -dihydroxypyrrbidin-1-yl-) -
(2R) -hydroxy-3-
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-10-
oxypropyl] amide, the maximum dissolved drug concentration provided by the
amorphous
form of which is about 600 pg/mL, while the maximum dissolved drug
concentration provided
by the "A2" crystalline form is only 87 pg/mL, both as measured in pH 6.5 PBS
solution.
The amorphous form of the drug may be any form in which the drug is amorphous.
Examples of amorphous forms of drug include solid amorphous dispersions of
drug in a
polymer, such as disclosed in commonly assigned US published patent
application
2002/0009494A1 herein incorporated by reference. Alternatively, the drug may
be adsorbed
in amorphous form on a solid substrate, such as disclosed in commonly assigned
US
published patent application 2003/0054037A1, herein incorporated by reference.
As yet
another alternative, amorphous drug may be stabilized using a matrix material,
such as
disclosed in commonly assigned US Patent application 2003/0104063A1, herein
incorporated
by reference.
Another solubility-improved form of drug is drug in a semi-ordered state, such
as
disclosed in commonly assigned US Provisional Patent Application Serial No.
60/403,087
filed August 12, 2002, herein incorporated by reference.
In yet another embodiment, the solubility-improved form comprises small drug
particles that improve the dissolution rate of the drug relative to the bulk
crystalline form of the
drug. By small particle size is meant that the drug particles have a mean
diameter of less
than 50 microns, more preferably less than 20 microns, and even more
preferably less than
10 microns. A particularly preferred and simple method for forming small
particles of drug
involves breaking larger diameter particles into smaller diameter particles.
Particle size
reduction may be accomplished by any conventional method, such as by milling,
or grinding.
Exemplary milling devices include a chaser mill, ball mill, vibrating ball
mill, hammer mill,
impact grinding mill, fluid energy mill (jet mill), and centrifugal-impact
pulverizers.
Alternatively, small particles may be formed by atomization or precipitation.
A preferred
method for reducing the drug particle size is jet milling. Small drug
particles can also be
formed by other means, such as dissolution in a solvent such as alcohol or
water followed by
precipitation by mixing with a non-solvent. Another method to reduce particle
size is by
melting or dissolving the drug in a solvent and atomizing the resulting liquid
by spray
congealing or spray drying to form a powder. The size of the drug particles
needed to
enhance drug dissolution compared with the bulk crystalline form of the drug
will depend on
the particular drug. In general, however, dissolution rate tends to increase
as the drug
particle size decreases. The average particle size may be less than 100
microns, less than
50 microns, or even less than 10 microns. For example, in the case of the drug
ziprasidone,
jet-milled ziprasidone may have a mean particle size of less than about 10
microns, and more
preferably less than about 5 microns. As described above, when a solubility
improved form of
the a drug, such as a salt, is dosed to a buffered solution, such as phosphate
buffered saline,
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-11-
with a pH of about 6 to 7.5, a lower solubility form of the drug may
ultimately precipitate from
solution. In such cases, the maximum dissolved concentration achieved is
determined by the
relative values of dissolution of the solubility improved drug form and the
precipitation or
crystallization rate of the lower solubility form. Thus, increasing the rate
of dissolution of the
drug by reduction of particle size can yield at least temporarily a higher
maximum drug
concentration than that achieved by dissolution of larger drug particles.
Another solubility-improved form of a drug comprises drug combined with a
cyclodextrin as an inclusion complex. As used herein, the term "cyclodextrin"
refers to all
forms and derivatives of cyclodextrin. Particular examples of cyclodextrin
include
a-cyclodextrin, R-cyclodextrin, and y-cyclodextrin. Exemplary derivatives of
cyclodextrin
include mono- or polyalkylated (3-cyclodextrin, mono- or polyhydroxyalkylated
R-cyclodextrin,
such as hydroxypropyl a-cyclodextrin (hydroxypropylcyclodextrin), mono, tetra
or hepta-
substituted P-cyclodextrin, and sulfoalkyl ether cyclodextrins (SAE-CD), such
as
sulfobutylether cyclodextrin (SBECD). The drug and cyclodextrin are complexed
together.
For example, the active drug and sulfoalkyl ether cyclodextrin (SAE-CD) may be
preformed
into a complex prior to the preparation of the final formulation. The complex
may be formed
by lyophilizing both the drug and cyclodextrin together to form a co-lyophile.
Several methods, such as an in vitro dissolution test or a membrane permeation
test
may be used to determine if a form of the drug is a solubility-improved form
and the degree of
solubility improvement. An in vitro dissolution test may be performed by
adding the solubility-
improved form of drug to a dissolution test media, such as model fasted
duodenal (MFD)
solution, phosphate buffered saline (PBS) solution, or distilled water and
agitating to promote
dissolution. An appropriate PBS solution is an aqueous solution comprising 20
mM Na2HPO4,
47 mM KH2PO4, 87 mM NaCI, and 0.2 'mM KCI, adjusted to pH 6.5 with NaOH. An
appropriate MFD solution is the same PBS solution wherein there is also
present 7.3 mM
sodium taurocholic acid and 1.4 mM of 1-palmitoyl-2-oleyl-sn-glycero-3-
phosphocholine.
Water is a preferred dissolution media for some fast precipitating salts. In
cases where the
solubility-improved form is an ionic salt of the drug it is often observed
that when neutral
buffer solutions (pH 6 to 8) are used, the solubility-improved form rapidly
converts to the
lowest energy form of the drug, typically the neutral crystalline form. In
such cases it may be
preferred to use an unbuffered test medium such as distilled water as the
dissolution medium.
In one method for evaluating whether the form is a solubility-improved form,
the
solubility-improved form of the drug when tested in an in vitro dissolution
test meets at least
one, and preferably both, of the following conditions. The first condition is
that the solubility-
improved form provides a higher maximum dissolved drug concentration (MDC) of
drug in the
in vitro dissolution test relative to a control composition consisting of the
lowest solubility
crystalline form of the drug. That is, once the solubility-improved form is
introduced into a use
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-12-
environment, the solubility-improved form provides a higher aqueous
concentration of
dissolved drug relative to the control composition. The control composition is
the lowest
solubility, bulk crystalline form of the drug alone. Preferably, the
solubility-improved form
provides an MDC of drug in aqueous solution that is at least 1.25-fold that of
the control
composition, more preferably at least 2-foid, and most preferably at least 3-
fold. For example,
if the MDC provided by the test composition is 22 pg/mI, and the MDC provided
by the control
composition is 2 pg/ml, the solubility-improved form provides an MDC that is
11-fold that
provided by the control composition.
The second condition is that the solubility-improved form provides a higher
dissolution
area under the concentration versus time curve (AUC) of dissolved drug in the
in vitro
dissolution test relative to a control composition consisting of an equivalent
amount of drug
alone. More specifically, in the in vitro use environment, the solubility-
improved form provides
an AUC for any 90-minute period from about 0 to about 270 minutes following
introduction to
the use environment that is at least 1.25-fold that of the control composition
described above.
Preferably, the AUC provided by the composition is at least 2-fold, more
preferably at least 3-
fold that of the control composition.
An in vitro test to evaluate enhanced drug concentration in aqueous solution
can be
conducted by (1) adding with agitation a sufficient quantity of control
composition, that is, the
lowest solubility crystalline drug alone, to the in vitro test medium, such as
distilled water or
an MFD or a PBS solution, to achieve equilibrium concentration of drug; (2) in
a separate test,
adding with agitation a sufficient quantity of test composition (e.g., the
solubility-improved
form) in the same test medium, such that if all drug dissolved, the
theoretical concentration of
drug would exceed the equilibrium concentration provided by the control
composition by a
factor of at least 2, and preferably by a factor of at least 10; and (3)
comparing the measured
MDC and/or aqueous AUC of the test composition in the test medium with the
equilibrium
concentration, and/or with the aqueous AUC of the control composition. In
conducting such a
dissolution test, the amount of test composition or control composition used
is an amount
such that if all of the drug dissolved, the drug concentration would be at
least 2-fold,
preferably at least 10-fold, and most preferably at least 100-fold that of the
equilibrium
concentration.
The concentration of dissolved drug is typically measured as a function of
time by
sampling the test medium and plotting drug concentration in the test medium
vs. time so that
the MDC can be ascertained. The MDC is taken to be the maximum value of
dissolved drug
measured over the duration of the test. The aqueous AUC is calculated by
integrating the
concentration versus time curve over any 90-minute time period between the
time of
introduction of the composition into the aqueous use environment (when time
equals zero)
and 270 minutes following introduction to the use environment (when time
equals 270
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-13-
minutes). Typically, when the composition reaches its MDC rapidly, (in less
than about 30
minutes), the time interval used to calculate AUC is from time equals zero to
time equals
90 minutes. However, if the AUC of a composition over any 90-minute time
period described
above meets the criterion of this invention, then the drug is considered to be
in a solubility-
improved form.
To avoid large drug particulates that would give an erroneous determination,
the test
solution is either filtered or centrifuged. "Dissolved drug" is typically
taken as that material
that either passes a 0.45 pm syringe filter or, alternatively, the material
that remains in the
supernatant following centrifugation. Filtration can be conducted using a 13
mm, 0.45 pm
polyvinylidine difluoride syringe filter sold by Scientific Resources under
the trademark
TITAN . Centrifugation is typically carried out in a polypropylene
microcentrifuge tube by
centrifuging at 13,000 G for 60 seconds. Other similar filtration or
centrifugation methods can
be employed and useful results obtained. For example, using other types of
microfilters may
yield values somewhat higher or lower ( 10-40%) than that obtained with the
filter specified
above but will still allow identification of preferred solubility-improved
forms. It should be
recognized that this definition of "dissolved drug" encompasses not only
monomeric solvated
drug molecules but also a wide range of species such as polymer/drug
assemblies that have
submicron dimensions such as drug aggregates, aggregates of mixtures of
polymer and drug,
micelles, polymeric micelles, colloidal particles or nanocrystals,
polymer/drug complexes, and
other such drug-containing species that are present in the filtrate or
supernatant in the
specified dissolution test.
In another method for evaluation of whether a drug form is a solubility-
improved form,
the dissolution rate of the solubility improved form is measured and compared
to the
dissolution rate of the bulk crystalline form of the lowest solubility form of
the drug. I The
dissolution rate may be tested in any appropriate dissolution media, such as
PBS solution,
MFD solution, or distilled water. Distilled water is a preferred dissolution
media for salt forms
that rapidly precipitate. The dissolution rate of the solubility-improved form
is greater than the
dissolution rate of the lowest solubility form of the drug in its bulk
crystalline form. Preferably,
the dissolution rate is 1.25-fold that of the lowest solubility form of the
drug, more preferably at
least 2-fold, and even more preferably at least 3-fold that of the lowest
solubility form of the
drug.
Alternatively, an in vitro membrane-permeation test may be used to determine
if the
drug is in a solubility-improved form. In this test, the solubility-improved
form is placed in,
dissolved in, suspended in, or otherwise delivered to the aqueous solution to
form a feed
solution. The aqueous solution can be any physiologically relevant solution,
such as an MFD
or PBS solution, as described above. After forming the feed solution, the
solution may be
agitated to dissolve or disperse the solubility-improved form therein or may
be added
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-14-
immediately to a feed solution reservoir. Alternatively, the feed solution may
be prepared
directly in a feed solution reservoir. Preferably, the feed solution is not
filtered or centrifuged
after administration of the solubility-improved form prior to performing the
membrane-
permeation test.
The feed solution is then placed in contact with the feed side of a
microporous
membrane, the feed side surface of the microporous membrane being hydrophilic.
The
portion of the pores of the membrane that are not hydrophilic are filled with
an organic fluid,
such as a mixture of decanol and decane, and the permeate side of the membrane
is in fluid
communication with a permeate solution comprising the organic fluid. Both the
feed solution
and the organic fluid remain in contact with the microporous membrane for the
duration of the
test. The length of the test may range from several minutes to several hours
or even days.
The rate of transport of drug from the feed solution to the permeate solution
is
determined by measuring the concentration of drug in the organic fluid in the
permeate
solution as a function of time or by measuring the concentration of drug in
the feed solution as
a function of time, or both. This can be accomplished by methods well known in
the art,
including by use of ultraviolet/visible (UVNis) spectroscopic analysis, high-
performance liquid
chromatography (HPLC), gas chromatography (GC), nuclear magnetic resonance
(NMR),
infra red (IR) spectroscopic analysis, polarized light, density, and
refractive index. The
concentration of drug in the organic fluid can be determined by sampling the
organic fluid at
discrete time points and analyzing for drug concentration or by continuously
analyzing the
concentration of drug in the organic fluid. For continuous analysis, UVNis
probes may be
used, as can flow-through cells. In all cases, the concentration of drug in
the organic fluid is
determined by comparing the results against a set of standards, as well known
in the art.
From these data, the maximum flux of drug across the membrane is calculated by
multiplying the maximum slope of the concentration of drug in the permeate
solution versus
time plot by the permeate volume and dividing by the membrane area. This
maximum slope
is typically determined during the first 10 to 90 minutes of the test, where
the concentration of
drug in the permeate solution often increases at a nearly constant rate
following a short time
lag of a few minutes. At longer times, as more of the drug is removed from the
feed solution,
the slope of the concentration versus time plot decreases. Often, the slope
approaches zero
as the driving force for transport of drug across the membrane approaches
zero; that is, the
drug in the two phases approaches equilibrium. The maximum flux is determined
either from
the linear portion of the concentration versus time plot, or is estimated from
a tangent to the
concentration versus time plot at time where the slope is at its highest value
if the curve is
non-linear. Further details of this membrane-permeation test are presented in
co-pending
U.S. Patent Application Serial No. 60/557,897, entitled "Method and Device for
Evaluation of
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-15-
Pharmaceutical Compositions," filed March 30, 2004 (attorney Docket No.
PC25968),
incorporated herein by reference.
A typical in vitro membrane-permeation test to evaluate solubility-improved
drug
forms can be conducted by (1) administering a sufficient quantity of test
composition (that is,
the solubility-improved form of the drug) to a feed solution, such that if all
of the_ drug
dissolved, the theoretical concentration of drug would exceed the equilibrium
concentration of
the drug by a factor of at least 2; (2) in a separate test, adding an
equivalent amount of
control composition (that is, the lowest solubility form of the drug) to an
equivalent amount of
test medium; and (3) determining whether the measured maximum flux of drug
provided by
the test composition is at least 1.25-fold that provided by the control
composition. A
composition is a solubility-improved form if, when dosed to an aqueous use
environment, it
provides a maximum flux of drug in the above test that is at least about 1.25-
fold the
maximum flux provided by the control composition. Preferably, the maximum flux
provided by
the compositions are at least about 1.5-fold, more preferably at least about 2-
fold, and even
more preferably at least about 3-fold that provided by the control
composition.
Precipitation-inhibiting Polymers
Precipitation-inhibiting polymers suitable for use with the present invention
should be
inert, in the sense that they do not chemically react with drug in an adverse
manner, are,
pharmaceutically acceptable, and have at least some solubility in aqueous
solution at
physiologically relevant pHs (e.g. 1-8). The polymer can be neutral or
ionizable, and should
have an aqueous-solubility of at least 0.1 mg/mL over at least a portion of
the pH range of
1-8.
Precipitation-inhibiting polymers suitable for use with the present invention
may be
cellulosic or non-cellulosic. The polymers may be neutral or ionizable in
aqueous solution. Of
these, ionizable and cellulosic polymers are preferred, with ionizable
cellulosic polymers
being more preferred.
A preferred class of precipitation-inhibiting polymers comprises polymers that
are
"amphiphilic" in nature, meaning that the polymer has hydrophobic and
hydrophilic portions.
The hydrophobic portion may comprise groups such as aliphatic or aromatic
hydrocarbon
groups. The hydrophilic portion may comprise either ionizable or non-ionizable
groups that
are capable of hydrogen bonding such as hydroxyls, carboxylic acids, esters,
amines or
amides.
One class of precipitation-inhibiting polymers suitable for use with the
present
invention comprises neutral non-cellulosic polymers. Exemplary polymers
include: vinyl
polyniers and copolymers having substituents of hydroxyl, alkylacyloxy, or
cyclicamido;
polyvinyl alcohols that have at least a portion of their repeat units in the
unhydrolyzed (vinyl
acetate) form; polyvinyl alcohol polyvinyl acetate copolymers; polyvinyl
pyrrolidone;
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-16-
polyoxyethylene-polyoxypropylene copolymers, also known as poloxamers; and
polyethylene
polyvinyl alcohol copolymers.
Another class of precipitation-inhibiting polymers suitable for use with the
present
invention comprises ionizable non-cellulosic polymers. Exemplary polymers
include:
carboxylic acid-functionalized vinyl polymers, such as the carboxylic acid
functionalized
polymethacrylates and carboxylic acid functionalized polyacrylates such as the
EUDRAGITSO manufactured by Rohm Tech Inc., of Malden, Massachusetts; amine-
functionalized polyacrylates and polymethacrylates; proteins; and carboxylic
acid
functionalized starches such as starch glycolate.
Non-cellulosic polymers that are amphiphilic are copolymers of a relatively
hydrophilic
and a relatively hydrophobic monomer. Examples include acrylate and
methacrylate
copolymers, and polyoxyethylene-polyoxypropylene copolymers. Exemplary
commercial
grades of such copolymers include the EUDRAGITS, which are copolymers of
methacrylates
and acrylates, and the PLURONICS or LUTROLS, supplied by BASF, which are
polyoxyethylene-polyoxypropylene copolymers.
A preferred class of precipitation-inhibiting polymers comprises ionizable and
neutral
cellulosic polymers with at least one ester- and/or ether-linked substituent
in which the
polymer has a degree of substitution of at least 0.1 for each substituent.
It should be noted that in the polymer nomenclature used herein, ether-linked
substituents are recited prior to "cellulose" as the moiety attached to the
ether group; for
example, "ethylbenzoic acid cellulose" has ethoxybenzoic acid substituents.
Analogously,
ester-linked substituents are recited after "cellulose" as the carboxylate;
for example,
"cellulose phthalate" has one carboxylic acid of each phthalate moiety ester-
linked to the
polymer and the other carboxylic acid unreacted.
It should also be noted that a polymer name such as "cellulose acetate
phthalate"
(CAP) refers to any of the family of cellulosic polymers that have acetate and
phthalate
groups attached via ester lirikages to a significant fraction of the
cellulosic polymer's hydroxyl
groups. Generally, the degree of substitution of each substituent group can
range from 0.1 to
2.9 as long as the other criteria of the polymer are met. "Degree of
substitution" refers to the
average number of the three hydroxyls per saccharide repeat unit on the
cellulose chain that
have been substituted. For example, if all of the hydroxyls on the cellulose
chain have been
phthalate substituted, the phthalate degree of substitution is 3. Also
included within each
polyrrier family type are cellulosic polymers that have additional
substituents added in
relatively small amounts that do not substantially alter the performance of
the polymer.
Amphiphilic cellulosics comprise polymers in which the parent cellulosic
polymer has
been substituted at at least a portion of the hydroxyl groups present on the
saccharide repeat
units of the polymer with at least one relatively hydrophobic substituent.
Hydrophobic
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-17-
substituents may be essentially any substituent that, if substituted to a high
enough level or
degree of substitution, can render the cellulosic polymer essentially aqueous
insoluble.
Examples of hydrophobic substituents include ether-linked alkyl groups such as
methyl, ethyl,
propyl, butyl, etc.; or ester-linked aikyl groups such as acetate, propionate,
butyrate, etc.; and
ether- and/or ester-linked aryl groups such as phenyl, benzoate, or phenylate.
Hydrophilic
regions of the polymer can be either those portions that are relatively
unsubstituted, since the
unsubstituted hydroxyls are themselves relatively hydrophilic, or those
regions that are
substituted with hydrophilic substituents. Hydrophilic substituents include
ether- or ester-
linked nonionizable groups such as the hydroxy alkyl substituents
hydroxyethyl,
hydroxypropyl, and the alkyl ether groups such as ethoxyethoxy or
methoxyethoxy.
Particularly preferred hydrophilic substituents are those that are ether- or
ester-linked
ionizable groups such as carboxylic acids, thiocarboxylic acids, substituted
phenoxy groups,
amines, phosphates or sulfonates.
One class of cellulosic polymers comprises neutral polymers, meaning that the
polymers are substantially non-ionizable in aqueous solution. Such poiymers
contain non-
ionizable substituents, which may be either ether-linked or ester-linked.
Exemplary ether-
linked non-ionizable substituents include: alkyl groups, such as methyl,
ethyl, propyl, butyl,
etc.; hydroxy alkyl groups such as hydroxymethyl, hydroxyethyl, hydroxypropyl,
etc.; and aryl
groups such as phenyl. Exemplary ester-linked non-ionizable substituents
include: alkyl
20. groups, such as acetate, propionate, butyrate, etc.;. and aryl groups such
as phenylate.
However, when aryl groups are included, the polymer may need to include a
sufficient amount
of a hydrophilic substituent so that the polymer has at least some water
solubility at any
physiologically relevant pH of from I to 8.
Exemplary non-ionizable polymers that may be used as the polymer include:
hydroxypropyl methyl cellulose acetate, hydroxypropyl methyl cellulose,
hydroxypropyl
cellulose, methyl cellulose, hydroxyethyl methyl cellulose, hydroxyethyl
cellulose acetate, and
hydroxyethyl ethyl cellulose.
A preferred set of neutral cellulosic polymers are those that are amphiphilic.
Exemplary polymers include hydroxypropyl methyl ceilulose and hydroxypropyl
methyl
cellulose acetate, where cellulosic repeat units that have relatively high
numbers of methyl or
acetate substituents relative to the unsubstituted hydroxyl or hydroxypropyl
substituents
constitute hydrophobic regions relative to other repeat units on the polymer.
Neutral polymers
suitable for use in the present invention are more fully disclosed in commonly
assigned
pending US Patent Application Serial No. 10/175,132, filed June 18, 2002,
herein
incorporated by reference.
A preferred class of cellulosic polymers comprises polymers that are at least
partially
ionizable at physiologically relevant pH and include at least one ionizable
substituent, which
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-18-
may be either ether-linked or ester-linked. Exemplary ether-linked ionizable
substituents
include: carboxylic acids, such as acetic acid, propionic acid, benzoic acid,
salicylic acid.,
alkoxybenzoic acids such as ethoxybenzoic acid or propoxybenzoic acid, the
various isomers
of alkoxyphthalic acid such as ethoxyphthalic acid and ethoxyisophthalic acid,
the various
isomers of alkoxynicotinic acid such as ethoxynicotinic acid, and the various
isomers of
picolinic acid such as ethoxypicolinic acid, etc.; thiocarboxylic acids, such
as thioacetic acid;
substituted phenoxy groups, such as hydroxyphenoxy, etc.; amines, such as
aminoethoxy,
diethylaminoethoxy, trimethylaminoethoxy, etc.; phosphates, such as phosphate
ethoxy; and
sulfonates, such as sulphonate ethoxy. Exemplary ester linked ionizable
substituents include:
carboxylic acids, such as succinate, citrate, phthalate, terephthalate,
isophthalate, trimellitate,
and the various isomers of pyridinedicarboxylic acid, etc.; thiocarboxylic
acids, such as
thiosuccinate; substituted phenoxy groups, such as amino salicylic acid;
amines, such as
natural or synthetic amino acids, such as alanine or phenylalanine;
phosphates, such as
acetyl phosphate; and sulfonates, such as acetyl sulfonate. For aromatic-
substituted
polymers to also have the requisite aqueous solubility, it is also desirable
that sufficient
hydrophilic groups such as hydroxypropyl or carboxylic acid functional groups
be attached to
the polymer to render the polymer aqueous soluble at least at pH values where
any ionizable
groups are ionized. In some cases, the aromatic group may itself be ionizable,
such as
phthalate or trimellitate substituents.
Exemplary cellulosic polymers that are at least partially ionized at
physiologically
relevant pHs include: hydroxypropyl methyl cellulose acetate succinate,
hydroxypropyl
methyl cellulose succinate, hydroxypropyl cellulose acetate succinate,
hydroxyethyl methyl
cellulose succinate, hydroxyethyl cellulose acetate succinate, hydroxypropyl
methyl cellulose
phthalate, hydroxyethyl methyl cellulose acetate succinate, hydroxyethyl
methyl cellulose
acetate phthalate, carboxyethyl cellulose, carboxymethyl cellulose,
carboxymethyl ethyl
cellulose, cellulose acetate phthalate, methyl cellulose acetate phthalate,
ethyl cellulose
acetate phthalate, hydroxypropyl cellulose acetate phthalate, hydroxypropyl
methyl cellulose
acetate phthalate, hydroxypropyl cellulose acetate phthalate succinate,
hydroxypropyl methyl
cellulose acetate succinate phthalate, hydroxypropyl methyl cellulose
succinate phthalate,
cellulose propionate phthalate, hydroxypropyl cellulose butyrate phthalate,
cellulose acetate
trimellitate, methyl cellulose acetate trimellitate, ethyl cellulose acetate
trimellitate,
hydroxypropyl cellulose acetate trimellitate, hydroxypropyl methyl cellulose
acetate
trimellitate, hydroxypropyl cellulose acetate trimellitate succinate,
cellulose propionate
trimellitate, cellulose butyrate trimellitate, cellulose acetate
terephthalate, cellulose acetate
isophthalate, cellulose acetate pyridinedicarboxylate, salicylic acid
cellulose acetate,
hydroxypropyl salicylic acid cellulose acetate, ethylbenzoic acid cellulose
acetate,
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-19-
hydroxypropyl ethylbenzoic acid cellulose acetate, ethyl phthalic acid
cellulose acetate, ethyl
nicotinic acid cellulose acetate, and ethyl. picolinic acid cellulose acetate.
Exemplary cellulosic polymers that meet the definition of amphiphilic, having
hydrophilic and hydrophobic regions include polymers such as cellulose acetate
phthalate
and cellulose acetate trimellitate where the cellulosic repeat units that have
one or more
acetate substituents are hydrophobic relative to those that have no acetate
substituents or
have one or more ionized phthaiate or trimellitate substituents.
A particularly desirable subset of cellulosic ionizable polymers are those
that possess
both a carboxylic acid functional aromatic substituent and an alkylate
substituent and thus are
amphiphilic. Exemplary polymers include cellulose acetate phthalate, methyl
cellulose
acetate phthalate, ethyl cellulose acetate phthalate, hydroxypropyl cellulose
acetate
phthalate, hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl
cellulose acetate
phthalate, hydroxypropyl cellulose acetate phthalate succinate, cellulose
propionate
phthalate, hydroxypropyl cellulose butyrate phthalate, cellulose acetate
trimellitate, methyl
cellulose acetate trimellitate, ethyl cellulose acetate trimellitate,
hydroxypropyl cellulose
acetate trimellitate, hydroxypropyl methyl cellulose acetate trimellitate,
hydroxypropyl
cellulose acetate trimellitate succinate, cellulose propionate trimellitate,
cellulose butyrate
trimellitate, cellulose acetate terephthalate, cellulose acetate isophthalate,
cellulose acetate
pyridinedicarboxylate, salicylic acid cellulose acetate, hydroxypropyl
salicylic acid cellulose
acetate, ethylbenzoic acid cellulose acetate, hydroxypropyl ethylbenzoic acid
cellulose
acetate, ethyl phthalic acid cellulose acetate, ethyl nicotinic acid cellulose
acetate, and ethyl
picolinic acid cellulose acetate.
Another particularly desirable subset of cellulosic ionizable polymers are
those that
possess a non-aromatic carboxylate substituent. Exemplary polymers include
hydroxypropyl
methyl cellulose acetate succinate, hydroxypropyl methyl cellulose succinate,
hydroxypropyl
cellulose acetate succinate, hydroxyethyl methyl cellulose acetate succinate,
hydroxyethyl
methyl cellulose succinate, hydroxyethyl cellulose acetate succinate, and
carboxymethyl ethyl
cellulose.
While, as listed above, a wide range of polymers may be used, the inventors
have
found that relatively hydrophobic polymers have shown the best performance as
demonstrated in vitro dissolution tests. In particular, cellulosic polymers
that are aqueous
insoluble in their nonionized state but are aqueous soluble in their ionized
state perform
particularly well. A particular subclass of such polymers are the so-called
"enteric" polymers,
which include, for example, hydroxypropyl methyl cellulose acetate succinate
(HPMCAS),
hydroxypropyl methyl cellulose phthalate (HPMCP), cellulose acetate phthalate
(CAP),
cellulose acetate trimellitate (CAT), and carboxymethyl ethyl cellulose
(CMEC). In addition,
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-20-
non-enteric grades of such polymers, as well as closely related cellulosic
polymers, are
expected to perform well due to the similarities in physical properties.
Thus, especially preferred polymers are hydroxypropyl methyl cellulose acetate
succinate (HPMCAS), hydroxypropyl methyl cellulose phthalate (HPMCP),
cellulose acetate
phthalate (CAP), cellulose acetate trimellitate (CAT), methyl cellulose
acetate phthalate,
hydroxypropyl methyl cellulose acetate phthalate, cellulose acetate
terephthalate, cellulose
acetate isophthalate, and carboxymethyl ethyl cellulose (CMEC). The most
preferred
ionizable cellulosic polymers are hydroxypropyl methyl cellulose acetate
succinate,
hydroxypropyl methyl cellulose phthalate, cellulose acetate phthaiate,
cellulose acetate
trimellitate, and carboxymethyl ethyl cellulose.
While specific polymers have been discussed as being suitable for use in the
dosage
forms of the present invention, blends of such polymers may also be suitable.
Thus the term
"polymer" is intended to include blends of polymers in addition to a single
species of polymer.
Another preferred class of polymers consists of neutralized acidic polymers.
By
"neutralized acidic polymer" is meant any acidic polymer for which a
significant fraction of the
"acidic moieties" or "acidic substituents" have been "neutralized"; that is,
exist in their
deprotonated form. By "acidic polymer" is meant any polymer that possesses a
significant
number of acidic moieties. In general, a significant number of acidic moieties
would be
greater than or equal to about 0.1 milliequivalents of acidic moieties per
gram of polymer.
"Acidic moieties" include any functional groups that are sufficiently acidic
that, in contact with
or dissolved in water, can at least partially donate a hydrogen cation to
water and thus
increase the hydrogen-ion concentration. This definition includes any
functional group or
"substituent," as it is termed when the functional group is covalently
attached to a polymer
that has a pKa, of less than about 10. Exemplary classes of functional groups
that are
included in the above description include carboxylic acids, thiocarboxylic
acids, phosphates,
phenolic groups, and sulfonates. Such functional groups may make up the
primary structure
of the polymer such as for polyacrylic acid, but more generally are covalently
attached to the
backbone of the parent polymer and thus are termed "substituents." Neutralized
acidic
polymers are described in more detail in commonly assigned copending US Patent
Application Serial No. 10/175,566 entitled "Pharmaceutical Compositions of
Drugs and
Neutralized Acidic Polymers" filed June 17, 2002, the relevant disclosure of
which is
incorporated by reference.
In addition, the preferred polymers listed above, that is amphiphilic
cellulosic
polymers, tend to have greater precipitation-inhibiting properties relative to
the other polymers
of the present invention. Generally those precipitation-inhibiting polymers
that have ionizable
substituents tend to perform best. In vitro tests of compositions with such
polymers tend to
have higher MDC and AUC values than compositions with other polymers of the
invention.
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-21-
The particles of low-solubility drug are at least partially coated with a
sufficient
amount of precipitation-inhibiting polymer to improve the concentration of
dissolved drug
relative to uncoated particles of the low-solubility drug alone (that is,
particles of drug in
solubility-improved form but no precipitation-inhibiting polymer). Several
methods, such as an
in vitro dissolution test or a membrane permeation test may be used to
evaluate precipitation-
inhibiting polymers and the degree of concentration enhancement provided by
the polymers.
It has been determined that enhanced drug concentration in in vitro
dissolution tests or in
membrane permeation tests in MFD solution or in PBS solution are good
indicators of in vivo
performance and bioavailability. When tested using an in vitro dissolution
test, described
above, the compositions meet at least one, and preferably both, of the
following conditions.
The first condition is that the composition increases the maximum dissolved
drug
concentration (MDC) of drug in the in vitro dissolution test relative to a
control composition
consisting of an equivalent amount of drug but no polymer. That is, once the
composition is
introduced into an environment of use, the composition provides an increased
aqueous MDC
of drug relative to the control composition. The control composition consists
of the solubility-
improved form of drug alone (without the precipitation-inhibiting polymer).
Preferably, the
inventive compositions provide an MDC of drug in aqueous solution that is at
least 1.25-fold
that of the control composition, more preferably at least 2-fold, and most
preferably at least 3-
fold. For example, if the MDC provided by the test composition is 5 mg/ml, and
the MDC
provided by the control composition is I mg/mI, the test composition provides
an MDC that is
5 fold that provided by the control composition.
The second condition is that the polymer coated drug particle composition
provides
an increased dissolution area under the concentration versus time curve (AUC)
of drug in the
in vitro dissolution test relative to a control composition consisting of an
equivalent amount. of
the drug in solubility-improved form but no polymer. (The calculation of an
AUC is a well-
known procedure in the pharmaceutical arts and is described, for example, in
Welling,
"Pharmacokinetics Processes and Mathematics," ACS Monograph 185 (1986).) More
specifically, in the environment of use, the composition of low-solubility
drug and polymer
provides an AUC for any 90-minute period of from about 0 to about 270 minutes
following
introduction to the use environment that is at least 1.25-fold that of the
control composition
described above. Preferably, the AUC provided by the composition is at least 2-
fold, more
preferably at least 3-fold that of the control composition.
A typical in vitro test to evaluate enhanced drug concentration in aqueous
solution
can be conducted by (1) adding with agitation a sufficient quantity of control
composition, that
is, the solubility-improved form of the drug alone, to the in vitro test
medium, such as an MFD
or a PBS solution, to achieve equilibrium concentration of drug; (2) in a
separate test, adding
with agitation a sufficient quantity of test composition (e.g., 'the
composition comprising
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-22-
polymer coated drug particles) in the same test medium, such that if all drug
dissolved, the
theoretical concentration of drug would exceed the equilibrium concentration
of drug by a
factor of at least 2, and preferably by a factor of at least 10; and (3)
comparing the measured
MDC and/or aqueous AUC of the test composition in the test medium with the
equilibrium
concentration, and/or with the aqueous AUC of the control composition. In
conducting such a
dissolution test, the amount of test composition or control composition used
is an amount
such that if all of the drug dissolved, the drug concentration would be at
least 2-fold,
preferably at least 10-fold, and most preferably at least 100-fold that of the
equilibrium
concentration.
Alternatively, an in vitro membrane-permeation test may be used to determine
if the
polymer coated drug particle composition provides concentration enhancement
relative to the
control composition. In this test, described above, the composition is placed
in, dissolved in,
suspended in, or otherwise delivered to the aqueous solution to form a feed
solution. A
typical in vitro membrane-permeation test to evaluate polymer coated drug
particles can be
conducted by (1) administering a sufficient quantity of test composition (that
is, the solubility-
improved drug form coated with precipitation-inhibiting polymer) to a feed
solution, such that if
all of the drug dissolved, the theoretical concentration of drug would exceed
the equilibrium
concentration of the drug by a factor of at least 2; (2) in a separate test,
adding an equivalent
amount of control composition (that is, the solubility-improved form of the
drug alone) to an
equivalent amount of test medium; and (3) determining whether the measured
maximum flux
of drug provided by the test composition is at least 1.25-fold that provided
by the control
composition. The solubility-improved form and precipitation-inhibiting
polymer, when dosed to
an aqueous use environment, provide a maximum flux of drug in the above test
that is at least
about 1.25-fold the maximum flux provided by the control composition.
Preferably, the
maximum flux provided by the test composition is at least about 1.5-fold, more
preferably at
least about 2-fold, and even more preferably at least about 3-fold that
provided by the control
composition.
Alternatively, dosage forms containing the polymer coated solubility-improved
drug
form particles, when dosed orally to a human or other animal in the fasted
state, provide an
AUC in drug concentration in the blood that is at least about 1.25-fold,
preferably at least
about 2-fold, preferably at least about 3-fold, preferably at least about 5-
fold, and even more
preferably at least about 10-fold that observed when a control dosage form is
dosed. By drug
concentration in the blood is meant the concentration of drug in blood, in
serum, or in plasma.
The control dosage form is identical to the test dosage form, except with no
precipitation-
inhibiting polymer. It is noted that such dosage forms can also be said to
have a relative
bioavailability of from about 1.25-fold to about 10-fold that of the control
dosage form.
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-23-
Alternatively, the dosage forms, when dosed orally to a human or other animal,
provide a maximum concentration of drug in the blood (Cmax) that is at least
1.25-fold that
observed when a control dosage form is dosed. Preferably, the blood Cmax is at
least about 2-
fold, and more preferably at least about 3-fold that of the control
composition.
Relative bioavailability and Cmax provided by the dosage forms can be tested
in vivo in
animals or humans using conventional methods for making such a determination.
An in vivo
test, such as a crossover study, may be used to determine whether a dosage
form provides
an enhanced relative bioavailability or Cmax compared with a control dosage
form as
described above. In an in vivo crossover study a test dosage form of the
present invention
comprising polymer coated solubility-improved drug form particles is dosed to
half a group of
test subjects and, after an appropriate washout period (e.g., one week) the
same subjects are
dosed with a control dosage form that is identical except with no polymer. The
other half of
the group is dosed with the control dosage form first, followed by the test
dosage form. The
relative bioavailability is measured as the concentration in the blood versus
time area under
the curve (AUC) determined for the test group divided by the AUC in the blood
provided by
the control composition. Preferably, this test/control ratio is determined for
each subject, and
then the ratios are averaged over all subjects in the study. In vivo
determinations of AUC and
Cmax can be made by plotting the blood concentration of drug along the
ordinate (y-axis)
against time along the abscissa (x-axis).
PROCESS FOR COATING DRUG PARTICLES
The drug particles may be at least partially coated with the precipitation-
inhibiting
polymer using any conventional method. The precipitation-inhibiting polymer
must be coated
onto the drug particles so that the precipitation-inhibiting polymer forms a
film or coating
directly on the surface of the drug particle. In general, the coating process
coats the
precipitation-inhibiting polymer directly onto at least a portion of the
surface of the drug
particles. This allows the drug and precipitation-inhibiting polymer to be in
direct contact with
one another, and not to be diluted relative to each other by other excipients.
The coating
process also coats the drug particles without creating large (e.g., >500 m)
aggregates of
drug and polymer. The resulting polymer coated drug particles should have a
mean diameter
of less than about 500 m, and should be free flowing so as to facilitate
blending of the
polymer coated particles with other excipients.
A preferred method to coat the drug particles with precipitation-inhibiting
polymer is to
spray dry the drug and precipitation-inhibiting polymer together. The term
"spray drying" is
used conventionally an=d broadly refers to processes involving breaking up
liquid mixtures or
suspensions into small droplets (atomization) and rapidly removing solvent
from the droplets
in a container where there is a strong driving force for evaporation of
solvent. This method
has particular utility when the drug particles are small (such as less than
200 microns).
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-24-
To at least partially coat the drug particles with precipitation-inhibiting
polymer by
spray drying, first a suspension of drug particles and dissolved precipitation-
inhibiting polymer
is formed in a solvent. The solvent is chosen based on the following
characteristics: (1) the
drug is insoluble or only slightly soluble in the solvent; (2) the polymer is
soluble in the
solvent; and (3) the solvent is relatively volatile. Preferably, the
solubility of the drug in the
solvent is less than 5 wt% of the amount of drug suspended in the spray
solution, more
preferably less than I wt% of the amount of drug suspended in the spray
solution, and even
more preferably less than 0.5 wt% of the amount of drug suspended in the spray
solution.
For example, if the spray solution contains 10 wt% drug, the drug preferably
has a solubility of
-10 less than 0.5 wt%, more preferably less than 0.1 wt%, and even more
preferably less than
0.05 wt% in the solvent. Preferred solvents include alcohols such as methanol,
ethanol, n-
propanol, iso-propanol, and butanol; ketones such as acetone, methyl ethyl
ketone and
methyl iso- butyl ketone; esters such as ethyl acetate and propylacetate; and
various other
solvents such as acetonitrile, methylene chloride, toluene, THF, cyclic
ethers, and 1,1,1-
trichloroethane. Mixtures of solvents, such as 50% methanol and 50% acetone,
may also be
used, as can mixtures with water as long as the poiymer is sufficiently
soluble to make the
spray-drying process practicable and as long as the drug is sufficiently
insoluble to remain in
suspension and not dissolved. In some cases it may be desired to add a small
amount of
water to aid solubility of the polymer in the spray solution.
The relative -amounts of drug suspended in the solvent and precipitation-
inhibiting
polymer dissolved in the solvent are chosen to yield the desired drug to
precipitation-inhibiting
polymer ratio in the resulting particles. For example, if a composition having
a drug to
precipitation-inhibiting polymer weight ratio of 0.33 (25 wt% drug) is
desired, then the spray
solution comprises 1 part drug and 3 parts precipitation-inhibiting polymer in
the solvent. The
total solids content of the spray solution is preferably sufficiently high so
that the spray
solution results in efficient production of the coated particles. The total
solids content refers to
the amount of solid drug, dissolved precipitation-inhibiting polymer and other
excipients
dissolved in the solvent. For exampie, to form a spray solution having a 5 wt%
dissolved
solids content and which results in a particle having a 25 wt% drug loading,
the spray solution
would comprise 1.25 wt% drug, 3.75 wt% precipitation-inhibiting polymer and 95
wt% solvent.
To achieve good yield, the spray solution preferably has a solids content of
at least 3 wt%,
more preferably at least 5 wt%, and even more preferably at least 10 wt%.
Given the wide
range of precipitation-inhibiting polymer molecular weights that may be
chosen, the best
solids content can vary widely from less than I wt% to more than 30 wt%.
However, the
solids content should not be too high, or else the spray solution may be too
viscous to
atomize efficiently into small droplets.
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-25-
Spray drying to form polymer coatings around drug particles is well known and
is
described in, for example, U.S. Patent No. 4,767,789, U.S. Patent No.
5,013,537, and U.S.
published patent application 2002/0064108A1, herein incorporated by reference.
Alternatively, the polymer may be coated around the drug crystals using a
rotary disk
atomizer, as described in US Patent No. 4,675,140, herein incorporated by
reference.
Alternatively, the precipitation-inhibiting polymer may be sprayed onto the
drug
particles in a high shear mixer or a fluid bed.
The amount of polymer coated onto the solubility-improved drug form is
sufficient to
provide concentration-enhancement of the drug relative to a control
composition consisting of
the drug alone as described above. Depending on the nature of the
precipitation-inhibiting
polymer and drug, the ratio of polymer to drug may vary from about 0.01 to
about 100. Good
results are generally achieved where the polymer to drug weight ratio is at
least about 0.11 (at
least about 10 wt% polymer), more preferably at least about 0.33 (at least
about 25 wt%
polymer), even more preferably at least about 0.66 (at least about 40 wt%
polymer), and even
more preferably at least about 1(at least about 50 wt% polymer). In a
preferred embodiment,
the polymer to drug weight ratio ranges from about 1 to about 4 (e.g., 50wt%
polymer to 80
wt% polymer). However, since it is often desired to limit the size of the
dosage form, the
amount of precipitation-inhibiting polymer may be less than the amount that
provides the
greatest degree of concentration enhancement. When calculating the weight
ratio of polymer
to drug, the weight of the polymer coated on the drug crystals is divided by
the total weight of
the drug, including any salts, waters of hydration, or solvates present in the
solubil.ity-
improved drug form.
EXCIPIENTS AND DOSAGE FORMS
Although the key ingredients present in the dosage forms of the present
invention are
simply the drug and polymer, the dosage form may include one or more
excipients.
Excipients may be utilized to formulate the drug and polymer into tablets,
capsules,
suspensions, powders for suspension, creams, transdermal patches, depots, and
the like.
One very useful class of excipients is surfactants. Suitable surfactants
include fatty
acid and alkyl sulfonates; commercial surfactants such as benzethanium
chloride
(HYAMINE(D 1622, available from Lonza, Inc., Fairlawn, N.J.); DOCUSATE SODIUM
(available from Mallinckrodt Spec. Chem., St. Louis, MO); polyoxyethylene
sorbitan fatty acid
esters (TWEEN , available from ICI Americas Inc., Wilmington, DE); LIPOSORB P-
20
(available from Lipochem Inc., Patterson NJ); CAPMUL POE-0 (available from
Abitec Corp.,
Janesville, WI), and natural surfactants such as sodium taurocholic acid, 1-
palmitoyl-2-oleoyl-
sn-glycero-3-phosphocholine, lecithin, and other phospholipids and mono- and
diglycerides.
Such materials can advantageously be employed to increase the rate of
dissolution by
facilitating wetting, thereby increasing the maximum dissolved concentration,
and also to
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-26-
inhibit crystallization or precipitation of drug by interacting with the
dissolved drug by
mechanisms such as complexation, formation of inclusion complexes, formation
of micelles or
adsorbing to the surface of solid drug: These surfactants may comprise up to 5
wt% of the
composition.
The addition of pH modifiers such as acids, bases, or buffers may also be
beneficial,
retarding or enhancing the rate of dissolution of the composition, or,
alternatively, helping to
improve the chemical stability of the composition.
Other conventional formulation excipients may be employed in the dosage forms
of
this invention, including those excipients well-known in the art (e.g., as
described in
Remington: The Science and Practice of Pharmacy (20th ed. 2000). Generally,
excipients
such as fillers, disintegrating agents, pigments, binders, lubricants,
glidants, flavorants, and
so forth may be used for customary purposes and in typical amounts without
adversely
affecting the properties of the compositions. These excipients may be utilized
after the
drug/polymer composition has been formed, in order to formulate the
composition into tablets,
capsules, suspensions, powders for suspension, creams, transdermal patches,
and the like.
Examples of fillers, or diluents include lactose, mannitol, xylitol, dextrose,
sucrose,
sorbitol, compressible sugar, microcrystalline cellulose, powdered cellulose,
starch,
pregelatinized starch, dextrates, dextran, dextrin, dextrose, maltodextrin,
calcium carbonate,
dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate,
magnesium
carbonate, magnesium oxide, poloxamers such as polyethylene oxide, and
hydroxypropyl
methyl cellulose.
Examples of drug complexing agents or solubilizers include the polyethylene
glycols,
caffeine, xanthene, gentisic acid and cylodextrins.
Examples of disintegrants include sodium starch glycolate, sodium
carboxymethyl
cellulose, calcium carboxymethyl cellulose, croscarmellose sodium,
crospovidone
(polyvinylpolypyrrolidone), methyl cellulose, microcrystalline cellulose,
powdered cellulose,
starch, pregelatinized starch, and sodium alginate.
Examples of tablet binders include acacia, alginic acid, carbomer,
carboxymethyl
cellulose sodium, dextrin, ethylceilulose, gelatin, guar gum, hydrogenated
vegetable oil,
hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl
cellulose, methyl
cellulose, liquid glucose, maltodextrin, polymethacrylates, povidone,
pregelatinized starch,
sodium alginate, starch, sucrose, tragacanth, and zein.
Examples of lubricants include calcium stearate, glyceryl monostearate,
glyceryl
palmitostearate, hydrogenated vegetable oil, light mineral oil, magnesium
stearate, mineral
oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium
stearyl fumarate, .
stearic acid, talc, and zinc stearate.
Examples of glidants include silicon dioxide, talc and cornstarch.
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-27-
Compositions of low-solubility drug and polymer of this invention may be used
in a
wide variety of dosage forms for administration of drugs. Exemplary dosage
forms are
powders or granules that may be taken orally either dry or reconstituted by
addition of water
to form a paste, slurry, suspension or solution; tablets; capsules;
multiparticulates; and pills.
Various additives may be mixed, ground, or granulated with the compositions of
this invention
to form a material suitable for the above dosage forms.
In some cases, the overall dosage form or particles, granules or beads that
make up
the dosage form may have superior performance if coated with an enteric
polymer to prevent
or retard dissolution until the dosage form leaves the stomach. Exemplary
enteric coating
materials include HPMCAS, HPMCP, CAP, CAT, carboxymethylethyl cellulose,
carboxylic
acid-functionalized polymethacrylates, and carboxylic acid-functionalized
polyacrylates.
Compositions of low-solubility drug and polymer of this invention may be
administered in a controlled release dosage form. In one such dosage form, the
composition
of the drug and polymer is incorporated into an erodible polymeric matrix
device. By an
erodible matrix is meant aqueous-erodible or water-swellable or aqueous-
soluble in the sense
of being either erodible or swellable or dissolvable in pure water or
requiring the presence of
an acid or base to ionize the polymeric matrix sufficiently to cause erosion
or dissolution.
When contacted with the aqueous environment of use, the erodible polymeric
matrix imbibes
water and forms an aqueous-swollen gel or "matrix" that entraps the particles
of low-solubility
drug that are at least partially coated with a precipitation-inhibiting
polymer. The aqueous-
swollen matrix gradually erodes, swells, disintegrates or dissolves in the
environment of use,
thereby controlling the release of the drug mixture to the environment of use.
Alternatively, the compositions of low-solubility drug and polymer of the
present
invention may be administered by or incorporated into a non-erodible matrix
device.
Alternatively, the drug and polymer may be delivered using a coated osmotic
controlled release dosage form. This dosage form tias two components: (a) the
core which
contains an osmotic agent and the coated drug particles; and (b) an outer
coating surrounding
the core, the outer coating controlling the influx of water to the core from
an aqueous
environment of use so as to cause drug release by extrusion of some or all of
the core to the
environment of use. The osmotic agent contained in the core of this device may
be an
aqueous-swellable hydrophilic polymer, hydrogel, osmogen, or osmagent. The
outer coating
surrounding the core is preferably polymeric, aqueous-permeable, and has at
least one
delivery port.
Alternatively, the drug and polymer may be delivered via a coated hydrogel
controlled
release dosage form having three components: (a) a drug-containing composition
containing
the coated drug particles, (b) a water-swellable composition wherein the water-
swellable
composition is in a separate region within a core formed by the drug-
containing composition
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-28-
and the water-swellable composition, and (c) an outer coating around the core
that is water-
permeable, and has at least one delivery port therethrough. In use, the core
imbibes water
through the outer coating, swelling the water-swellable composition and
increasing the
pressure within the core, and fluidizing the drug-containing composition.
Because the outer
coating surrounding the core remains intact, the drug-containing composition
is extruded out
of the delivery port into an environment of use.
In one embodiment, the dosage form provides controlled release of at least a
portion
of the drug contained in the dosage form over a sustained length of time. Such
an
embodiment may have utility where it is desired to release at least a portion
of the drug in the
small intestine, the colon, or both. In this embodiment, the drug may be
coated with an
enteric, precipitation-inhibiting polymer. Preferred enteric precipitation-
inhibiting polymers
include HPMCAS, CAP, CAT, HPMCP, and CMEC. The drug particles may be fully
encapsulated with the precipitation-inhibiting potymer to prevent early
dissolution of the drug
in a gastric environment. The precipitation-inhibiting polymer may be water
impermeable at
= 15 low pH to prevent the drug from dissolving and leaching out of the dosage
form in the gastric
environment. This embodiment has particular utility for providing controlled
release of low-
solubility, basic drugs to the small intestine or colon.
In addition to the above additives or excipients, use of any conventional
materials and
procedures for preparation of suitable dosage forms using the compositions of
this invention
known by those skilled in the art are potentially useful.
Other features and embodiments of the invention will become apparent from the
following examples that are given for illustration of the invention rather
than for limiting its
intended scope.
EXAM PLES
Coated Crystals 1 (CC-1)
In this example, ziprasidone hydrochloride monohydrate crystals were coated
with the
precipitation-inhibiting polymer hydroxypropyl methyl cellulose acetate
succinate (HPMCAS)
to form particles of a solubility-improved drug form at least partially coated
with a
precipitation-inhibiting polymer.
A microcentrifuge dissolution test was performed to verify that ziprasidone
hydrochloride monohydrate is a solubility-improved form of ziprasidone. For
this test, a
'sufficient amount of ziprasidone hydrochloride monohydrate was added to a
microcentrifuge
test tube so that the concentration of ziprasidone would have been 200 gA/mL,
if all of the
ziprasidone had dissolved. The tests were run in duplicate. The tubes were
placed in a 37 C
temperature-controlled chamber, and 1.8 mL MFD solution at pH 6.5 and 290
mOsm/kg was
added to each respective tube. The samples were quickly mixed using a vortex
mixer for
about 60 seconds. The samples were centrifuged at 13,000 G at 37 C for 1
minute prior to
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-29-
collecting a sample. The resulting supernatant solution was then sampled and
diluted 1:5 (by
volume) with methanol. Samples were analyzed by high-performance liquid
chromatography
(HPLC) at a UV absorbance of 315 nm using a Zorbax RxC8 Reliance column and a
mobile
phase consisting of 55% (50 mM potassium dihydrogen phosphate, pH 6.5)/45%
acetonitrile.
Drug concentration was calculated by comparing UV absorbance of samples to the
absorbance of drug standards. The contents of each tube were mixed on the
vortex mixer
and allowed to stand undisturbed at 37 C until the next sample was taken.
Samples were
collected at 4, 10, 20, 40, 90, and 1200 minutes following administration to
the MFD solution.
The results are shown in Table 1.
A similar test was performed with the crystalline ziprasidone free base as a
control,
and a sufficient arriount of material was added so that the concentration of
compound would
have been 200 pgA/mL, if all of the ziprasidone had dissolved.
TABLE 1
Salt Form JTime (min) Dissolved Ziprasidone Concentration (iagA/mL) AUC (min-
pgA/mL)
0 0 0
4 1 3
10 1 11
Ziprasidone
1 23
Free Base
40 2 51
90 1 120
1200 2 2000
0 0 0
4 14 30
Ziprasidone 10 15 110
hydrochloride 20 20 280
monohydrate 40 22 700
90 18 1,700
1200 9 16,400
15 The concentrations of ziprasidone obtained in these tests were used to
determine the
maximum dissolved concentration of ziprasidone ("MDC90") and the area under
the
concentration-versus-time curve ("AUC90") during the initial ninety minutes.
The results are
shown in Table 2.
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-30-
TABLE 2
Salt Form MDC9o (mgA/mL) AUC90 (min*mgA/mL)
Ziprasidone Free Base 2 120
Ziprasidone hydrochloride 22 1,700
monohydrate
These results show that ziprasidone hydrochloride monohydrate provided an
MDC90
that was 11-fold that provided by the free base, and an AUC90 that was 14-fold
that provided
by the free base. Thus, the hydrochloride salt form is a solubility-improved
form of
ziprasidone.
A spray drying process was used to form particles of ziprasidone hydrochloride
monohydrate at least partially coated with HPMCAS, as follows. The CC-1
formulation
contained 39.7 wt% jet-milled ziprasidone hydrochloride monohydrate coated
with the
precipitation-inhibiting polymer HPMCAS-HG (AQOAT-HG, manufactured by Shin
Etsu,
Tokyo, Japan). Thus, the weight ratio of polymer to drug was 1.52.
Jet-milled ziprasidone was prepared as follows. The ziprasidone dry powder was
slowly poured into a Glen Mills Laboratory Jet Mill, with two nitrogen lines
set at about 100
psi. Milled material was collected in a receiving jar.
A spray suspension was then formed containing 3.97 wt% jet-milled ziprasidone
hydrochloride monohydrate, 6.03 wt% HPMCAS-HG, and 90 wt% acetone. The acetone
and
HPMCAS-HG were combined in a container and mixed with a top-mounted mixer,
dissolving
the HPMCAS in the acetone. Jet-milled ziprasidone was added to the polymer
solution and
mixing continued witti a top-mounted mixer, forming a suspension of the
ziprasidone in the
polymer/acetone solution. Next, a re-circulation pump (Yamada air actuated
diaphragm pump
model NDP-5FST) was used to move the suspension to a high-shear in-line mixer
(Bematek
model LZ-150-6-PB multi-shear in-line mixer) equipped with a series of
rotor/stator shear
heads to break up any remaining drug crystal agglomerations. The high shear
mixer was
operated with a setting of 3500 500 rpm, for 45-60 minutes per 20 kg
solution. The re-
circulation pump pressure was 35 10 psig.
The suspension was then pumped using a high-pressure pump to a spray dryer (a
Niro type XP Portable Spray-Dryer with a Liquid-Feed Process Vessel ("PSD-
1")), equipped
with a pressure nozzle (Spraying Systems Pressure Nozzle and Body) (SK 74-20).
The PSD-
1 was equipped with a 5-foot 9-inch chamber extension. The chamber extension
was added
to the spray dryer to increase the vertical length of the dryer. The added
length increased the
residence time within the dryer, which allowed the product to dry before
reaching the angled
section of the spray dryer. The spray dryer was also equipped with a 316 SS
circular diffuser
plate with 1/1 6-inch drilled holes, having a 1% open area. This small open
area directed the
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-31-
flow of the drying gas to minimize product recirculation within the spray
dryer. The nozzle sat
flush with the diffuser plate during operation. The suspension was delivered
to the nozzle at
about 285 g/min at a pressure of about 350 psig. The pump was followed by a
pulsation
dampener to minimize pulsation at the nozzle. Drying gas (e.g., nitrogen) was
delivered
through the diffuser plate at a flow rate of 1550 g/min, and an inlet
temperature of 140 C. The
evaporated solvent and wet drying gas exited the spray drier at a temperature
of 40 C. The
coated crystals formed by this process were collected in a cyclone, then post-
dried using a
Gruenberg single-pass convection tray dryer operating at 40 C for 4 hours. The
properties of
the coated crystals after secondary drying were as follows:
TABLE 3
Parameter Value
Morphology Spherical and wrinkled particles
Mean particle diameter (pm) 44
*DvIo, Dv50, Dv90 (pm) 13, 40, 81
Span (Dso-Djo)/D50 1.7
Bulk specific volume (cc/g) 4.14
Tapped specific volume (cc/g) 2.65
Hausner ratio 1.56
* 10 vol% of the particles have a diameter that is smaller than Djo; 50 vol%
of the
particles have a diameter that is smaller than D50, and 90 vol% of the
particles have
a diameter that is smaller than D90.
In Vitro Dissolution Test
This describes an in vitro membrane permeation test, used to demonstrate that
the
coated crystals CC-1 provided concentration-enhancement of ziprasidone in
vitro. An
Accurel PP 1E microporous polypropylene membrane was obtained from Membrana
GmbH
(Wuppertal, Germany). The membrane was washed in isopropyl alcohol and rinsed
in
methanol in a sonicating bath for 1 minute at ambient temperature, and then
allowed to air dry
at ambient temperature. The feed side of the membrane was then plasma-treated
to render it
hydrophilic by placing a sample of the membrane in a plasma chamber. The
atmosphere of
the plasma chamber was saturated with water vapor at a pressure of 550 mtorr.
A plasma
was then generated using radio frequency (RF) power inductively coupled into
the chamber
via annular electrodes at a power setting of 50 watts for 45 seconds. The
contact angle of a
drop of water placed on the surface of the plasma-treated membrane was less
than about
40 . The contact angle of a drop of water placed on the permeate side of the
same
membrane was greater than about 1100.
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-32- -
A permeate reservoir was formed by gluing a sample of the plasma-treated
membrane to a glass tube having an inside diameter of about 1 inch (2.54 cm)
using an
epoxy-based glue (LOCTITEO E-30CL HYSOLO from Henkel Loctite Corp, Rocky Hill,
Connecticut). The feed-side of the membrane was oriented so that it was on the
outside of
the permeate reservoir, while the permeate-side of the membrane was oriented
so that it was
on the inside of the reservoir. The effective membrane area of the membrane on
the
permeate reservoir was about 4.9 cm2. The permeate reservoir was placed into a
glass feed
reservoir. The feed reservoir was equipped with a magnetic stir bar and the
reservoir was
placed on a stir plate and the stir rate was set to 100 rpm during the test.
The apparatus was
placed into a chamber maintained at 37 C for the duration of the test. Further
details of the
test apparatus and protocols are presented in co-pending U.S. Patent
Application Serial No.
60/557,897, entitled "Method and Device for Evaluation of Pharmaceutical
Compositions,"
filed March 30, 2004 (attorney Docket No. PC25968), incorporated herein by
reference.
To form the feed solution, a 1.429 mg (0.5 mgA) sample of CC-1 was weighed
into a
feed reservoir. (As used herein, "mgA" is milligrams of active drug, reported
as the free base,
non-salt form, non-hydrate drug molecule.) To this was added 5 mL of the MFD
solution
previously described, consisting of PBS solution containing 7.3 mM sodium
taurocholic acid
and 1.4 mM of 1-palmitoyl-2-oleyl-sn-glycero-3-phosphocholine (0.5%
NaTC/POPC). The
concentration of ziprasidone in the feed solution would have been 100 mg/mL,
if all of the
drug had dissolved. The feed solution was mixed using a vortex mixer for 1
minute. Before
the membrane contacted the feed solution, 5 mL of 60 wt% decanol in decane was
placed
into the permeate reservoir. Time zero in the test was when the membrane was
placed in
contact with the feed solution. A 50 mL aliquot of the permeate solution was
collected at the
times indicated. Samples were then diluted in 250 mL IPA and analyzed using
HPLC. The
results are shown in Table 4.
Control 1 A
Control IA consisted of crystalline jet-milled ziprasidone hydrochloride
monohydrate
(Control 1A) alone, in MFD solution, and a sufficient amount of material was
added so that the
concentration of drug would have been 100 iagA/mL, if all of the drug had
dissolved.
Control I B
Control 1 B consisted of crystalline ziprasidone free-base alone, in MFD
solution, and
a sufficient amount of material was added so that the concentration of drug
would have been
100 NgA/mL, if all of the drug had dissolved
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-33-
TABLE 4
Ziprasidone
Time Concentration in
Example
(min) Permeate
(pgA/mL)
0 0.5
20 4.5
40 10.0
60 15.5
CC-1 90 23.6
120 31.9
180 45.3
240 56.2
360 63.7
0 0.5
20 3.8
Control IA 40 6.0
Crystalline jet-
60 8.4
milled
90 12.4
ziprasidone
120 15.3
hydrochloride
180 20.6
monohydrate
240 25.2
360 30.6
0 0.0
20 0.0
40 3.3
Control 1 B
60 3.4
Crystalline
90 5.4
ziprasidone
120 6.8
free-base
180 9.2
245 11.5
360 14.7
The maximum flux of drug across the membrane (in units of gA/cm2-min) was
determined by performing a least-squares fit to the data in Table 4 from 0 to
60 minutes to
obtain the slope (CC-1: 0.26 gA/mL-min; Control 1A: 0.13 gA/mL-min; Control
1B: 0.07
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-34-
NgA/mL-min), multiplying the slope by the permeate vo{ume (5 mL), and dividing
by the
membrane area (4.9 cm2). The results of this analysis are summarized in Table
5 and show
that the maximum flux of ziprasidone through the membrane provided by the
formulation of
CC-1 was 2.0-fold that provided by Control 1 A, and 3.7-fold that provided by
Control 1 B.
TABLE5
Maximum Flux
Sample Formulation of Ziprasidone
( gA/cm2-min)
39.7 wt% jet-milled
ziprasidone hydrochloride
CC-1 0.26
monohydrate crystals coated
with HPMCAS-HG
Crystalline jet-milled
Control 1A ziprasidone hydrochloride 0.13
monohydrate
Crystalline ziprasidone free
Control 1 B 0.07
base
Coated Crystals 2 (CC-2)
Crystals of ziprasidone hydrochloride monohydrate were coated with the "HF"
grade
of HPMCAS (AQOAT-HF, Shin Etsu) using the procedures outlined for CC-1, except
that the
ziprasidone hydrochloride monohydrate was not jet milled prior to coating. The
coated
crystals contained 39.7 wt% ziprasidone hydrochloride monohydrate. The
pro,perties of CC-2
are given in Table 6.
TABLE 6
Parameter Value
Morphology Irregular spheres with evidence of crystalline
particles
Mean particle diameter (pm) 42
*Dvto, Dv80, Dvso (pm) . 13, 38, 76
Span (Dso-D1o)/Dso 1.6
Bulk specific volume (cc/g) 3.3
Tapped specific volume (cc/g) 2.2
Hausner ratio 1.5
An in vitro membrane permeation test was performed using the procedures
outline for
CC-1 to demonstrate that the coated crystals CC-2 provided concentration-
enhancement of
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-35-
ziprasidone in vitro. Table 7 shows the concentration of drug in the permeate
solution versus
time.
Control 2
Control 2 consisted of crystalline ziprasidone hydrochloride monohydrate
(Control 2)
alone, in MFD solution, and a sufficient amount of material was added so that
the
concentration of drug would have been 100 gA/mL, if all of the drug had
dissolved.
TABLE 7
Formulation Time (min) Concentration (pgA/mL)
0 0.0
20 3.4
40 13.2
60 17.5
CC-2 90 25.2
120 33.3
180 47.9
240 48.4
360 52.4
0 0.5
20 5.2
40 8.1
60 .10.0
Control 2 90 11.4
120 12.9
180 18.1
240 20.9
360 22.6
The maximum flux of drug across the membrane was determined by performing a
least-squares fit to the data in Table 7 from 0 to 60 minutes to obtain the
slope (CC-2: 0.32
NgA/mL-min; Control 2: 0.16 NgA/mL-min), multiplying the slope by the permeate
volume (5
mL), and dividing by the membrane area (4.9 cm2). The results of this analysis
are
summarized in Table 8. These data show that the maximum flux of ziprasidone
through the
membrane provided by the formulation of CC-2 was 2.0-fold that provided by
Control 2.
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-36-
TABLE 8
Maximum Flux of
Sample Formulation Ziprasidone
( gA/cm2-min)
39.7 wt% ziprasidone
hydrochloride monohydrate
CC-2 0.32
crystals coated with HPMCAS-
HG
Crystalline ziprasidone
Control 2 0.16
hydrochloride monohydrate
Coated Crystals 3 (CC-3)
Crystals of ziprasidone tosylate, a solubility-improved form of ziprasidone,
were
coated with the "HF" grade of HPMCAS (AQOAT-HF, Shin Etsu) using the
procedures
outlined for CC-1, with the following exceptions. The spray suspension was
formed by first
dissolving 12.07 gm HPMCAS-HF into 225 gm acetone and then suspending 12.94 gm
of
ziprasidone tosylate in the resulting solution. The coated crystals contained
52 wt%
ziprasidone tosylate, corresponding to a weight ratio of HPMCAS to ziprasidone
tosylate of
0.92.
An in vitro membrane permeation test was performed using the procedures
outline for
CC-1 to demonstrate that the coated crystals CC-3 provided concentration-
enhancement of
ziprasidone in vitro. Table 9 shows the concentration of drug in the permeate
solution versus
time.
Control3
Control 3 consisted - of crystalline ziprasidone tosylate (Control 3) alone,
in MFD
solution, and a sufficient amount of material was added so that the
concentration of drug
would have been 100 }LgA/mL, if all of the drug had dissolved.
TABLE 9
Formulation Time (min) Concentration (pgA/mL)
CC-3 0 0.0
14.4
40 23.9
60 28.3
90 31.7
120 34.9
180 38.4
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-37-
Formulation Time (min) Concentration (pgA/mL)
240 42.8
300 46.5
360 51.3
0 0.0
20 0.7
40 1.6
60 2.5
90 3.6
Control 3
120 4.6
180 7.1
240 10.1
300 12.6
360 14.7
The maximum flux of drug across the membrane was determined by performing a
least-squares fit to the data in Table 9 from 0 to 60 minutes to obtain the
slope (CC-3: 0.47
pgA/mL-min; Control 3: 0.04 pgA/mL-min), multiplying the slope by the permeate
volume (5
mL), and dividing by the membrane area (4.9 cm) . The results of this analysis
are
summarized in Table 10 and show that the maximum flux of ziprasidone through
the
membrane provided by the formulation of CC-3 was 12-fold that provided by
Control 3.
TABLE 10
Maximum Flux of
Sample Formulation Ziprasidone
( g/cm~-min)
52 wt% ziprasidone tosylate
CC-3 crystals coated with 0.48
HPMCAS-HF
Crystalline ziprasidone
Control 3 0.04
tosylate
Coated Crystals 4 (CC-4)
In this example, sildenafil citrate, a solubility-improved form of sildenafil,
was coated
with the precipitation-inhibiting polymer HPMCAS to form particles of a
solubility-improved
drug form at least partially coated with a precipitation-inhibiting polymer.
A spray drying process was used to form particles of sildenafil citrate coated
with
HPMCAS, as follows. The CC-4 formulation contained 75 wt% sildenafil citrate
coated with
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-38-
the precipitation-inhibiting polymer HPMCAS-HG (AQOAT-HG, manufactured by Shin
Etsu).
First, a spray suspension was formed containing 50 g sildenafil citrate, 16.65
g HPMCAS-HG,
and 266.6 g acetone. The acetone and HPMCAS-HG were combined in a container
and
mixed with a top-mounted mixer, dissolving the HPMCAS in the acetone.
Sildenafil citrate
was added to the polymer solution to form a suspension of the drug crystals,
and mixing
continued with a top-mounted mixer as described for CC-1. A re-circulation
pump was used
to move the suspension to a high-shear in line mixer. The high shear mixer was
operated
with a setting of 5000 rpm, for 7 minutes.
The suspension was then pumped using a high-pressure pump to the spray drier
described in CC-1. The PSD-1 was equipped with a 9-inch chamber extension. The
suspension was delivered to a Spraying Systems pressure nozzle SK 76-16 at
about 160
g/min at a pressure of about 200 psi. Drying gas (e.g., nitrogen) was
delivered through the
diffuser plate, with an inlet temperature of 105 C. The evaporated solvent and
wet drying gas
exited the spray drier at a temperature of 48 C. The coated crystals formed by
this process
were collected in a cyclone, then post-dried using a Gruenberg single-pass
convection tray
dryer operating at 30 C for 20 hours. The resulting coated crystals of
sildenafil had a ratio of
HPMCAS to drug of 0.33.
In Vitro Dissolution Test
The coated drug crystals of CC-4, and crystalline drug alone (Control 4), were
evaluated using a nuclear magnetic resonance (NMR) test to show that CC-4
provided
concentration-enhancement. In this test, 3.276 mg of the coated crystals CC-4,
or 2.542 mg
of Control 4 (sildenafil citrate alone), was added to microcentrifuge tubes in
duplicate. The
tubes were placed in a 37 C temperature-controlled chamber, and 1.8 mL of
deuterated PBS
solution at pH 6.5 and 290 mOsm/kg, with 3-(trimethylsilyl)propionic-2,2,3,3-
d4 acid, sodium
salt ("TSP"; a deuterated NMR reference standard), was added. The samples were
quickly
mixed using a vortex mixer for 60 seconds. The suspension was then immediately
transferred to an 8 mm glass NMR tube and acquisition was started as soon as
possible.
Proton spectra of the sample were recorded at 300.070 MHz on a Varian Gemini
2000, 300 MHz NMR equipped with a Nalorac 8 mm indirect detection probe. The
sample
temperature was maintained at 37 C in the probe and the spectra acquired using
a 90 pulse
width and 14 second pulse delay (delay > 5*t1 dr,9 or standard). Ten
consecutive free induction
decay signals (FIDs) were collected to determine the concentration, with each
FID consisting
of 120 pulses (30 minutes per FID). The listed time for each concentration
result (i.e., FID)
was calculated from the time the PBS solution was added to the solid sample
until half of the
time the FID had been acquired. For example, when the second FID was recorded
for a
sample that was started 5 minutes after the addition of PBS, the time listed
for the NMR result
was 50 minutes (5 min + 30 min [time for the first FID result] +1/2 of 30 min
[time of second
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-39-
FID result]). Aromatic drug resonances were integrated relative to the
internal standard peak
and the drug concentration determined.
The results of this test are summarized in Table 11, which shows the
concentration of
sildenafil in solution for CC-4 and Control 4. The coated crystals CC-4
provided an enhanced
dissolved drug concentration over that of the control.
TABLE 11
Sildenafil
Time
Sample (min) Concentration
( gA/mL)
20 185
50 163
80 153
110 150
140 143
CC-4
170 145
200 133
230 :127
260 134
290 127
30 27
60 24
90 25
120 24
150 21
Control 4
180 21
crystalline
210 24
sildenafil
240 27
citrate
270 25
300 28
330 22
360 21
390 33
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-40-
Dosage Form DF-1
Dosage Form DF-1 was prepared using coated crystals CC-2, consisting of 39.7
wt%
ziprasidone hydrochloride monohydrate coated with HPMCAS-HF. Dosage Form DF-1
was
prepared using the following procedure.
Preparation of the Drug-Containing Composition
To form the drug-containing composition, the following materials were blended:
24.99
wt% CC-2, 74.01 wt% polyethylene oxide (PEO WSR N80), and 1.00 wt% magnesium
stearate. The drug-containing composition ingredients were first combined with
0.25 wt%
magnesium stearate and blended for 15 minutes in a 16 quart V-blender. Next,
the
ingredients were roller-compacted using a Vector TF mini roller-compactor,
then milled using
a Fitzpatrick M5A mill. Finally, the drug-containing composition was blended
an additional 10
minutes, the remaining magnesium stearate (0.75 wt%) was added, and the
ingredients were
blended again for 5 minutes.
Preparation of the Water-Swellable Composition
To form the water-swellable composition, the following materials were blended:
65.0
wt% polyethylene oxide (PEO WSR coagulant), 34.3 wt% sodium chloride, 0.5 wt%
magnesium stearate, and 0.2 wt% Blue Lake #2. All ingredients except magnesium
stearate
were combined and blended for 15 minutes, then milled using a Fitzpatrick M5A
mill. The
ingredients were blended an additional 10 minutes, the magnesium stearate was
added, and
the mixture was blended again for 5 minutes.
Preparation of Tablet Cores
Bilayer tablet cores were manufactured using an Elizabeth-Hata trilayer press
combining 453 mg of the drug-containing composition and 227 mg of the water-
swellable
composition using 7/16-inch standard. round concave (SRC) plain-faced tooling.
The tablet
cores were compressed to a hardness of about 8 kiloponds (kp). The resulting
bi-layer tablet
core had a total weight of 680 mg and contained a total of 40 mg active
ziprasidone.
Application of the Coating
Coatings for the tablet cores were applied in a Vector LDCS-20 pan coater. The
coating solution for DF-1 contained cellulose acetate (CA 398-10 from Eastman
Fine
Chemical, Kingsport, Tennessee), polyethylene glycol (PEG 3350, Union
Carbide), water, and
acetone in a weight ratio of 6.8/1.2/4/88 (wt%). The flow rate of the inlet
heated drying gas of
the pan coater was set at 40 ft3/min with the outlet temperature set at 25 C.
Nitrogen at 20
psi was used to atomize the coating solution from the spray nozzle, with a
nozzle-to-bed
distance of 2 inches. The pan rotation was set to 20 rpm. The so-coated
tablets were dried
16 hr at 40 C in a tray-drier. The final dry coating weight amounted to about
8.1 wt% of the
tablet core. One 900 m diameter hole was laser-drilled in the coating on the
drug-containing
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-41-
composition side of each of the tablets of DF-1 to provide one delivery port
per tablet. Each
tablet of DF-1 contained 40 mgA of ziprasidone.
Dosage Form DF-2
Dosage Form DF-2 was prepared using the same procedure outlined for DF-1
except
that the coating amounted to 10 wt% of the core weight. Each tablet of DF-2
contained
40 mgA of ziprasidone.
Dosage Form DF-3
Dosage Form DF-3 was prepared using the procedures outlined for DF-1 except
that
the drug-containing composition used coated crystals CC-1. The coating
solution contained
CA 398-10, PEG 3350, water, and acetone in a weight ratio of
4.25/0.75/2.5/92.5 (wt%), and
amounted to 7.8 wt% of the core weight. Each tablet of DF-3 contained 40 mgA
of
ziprasidone.
Dosage Form DF-4
Dosage Form DF-4 was prepared using the same procedure outlined for DF-3
except
that the coating amounted to 10.2 wt% of the core weight. Each tablet of DF-4
contained
40 mgA of ziprasidone.
Dosage Form DF-5
Dosage Form DF-5 consisted of a matrix sustained-release tablet made using
coated
crystals CC-2. The matrix tablets consisted of 42 wt% of the coated- crystals
CC-2, 42 wt%
sorbitol, 15 wt% HPMC (K100LV), and 1 wt% magnesium stearate. The tabiets were
prepared by first blending the coated crystals, sorbitol, and HPMC in a twin-
shell blender for
20 minutes, milling using a Fitzpatric M5A mill, and then blending in the twin-
shell blender for
an additional 20 minutes. The magnesium stearate was then added and the
mixture blended
again for 5 minutes. The tablets were manufactured using an F press using
555.5 mg of the
mixture using 11-mm SRC plain-faced tooling. The tablet=cores were compressed
to a
hardness of about 11 kp. The resulting sustained-release matrix tablet
contained a total of 80
mg active ziprasidone.
Dosage Form DF-6
Dosage Form DF-6 consisted of a matrix sustained-release tablet made using
coated
crystals CC-2. The matrix tablets consisted of 30 wt% of the coated crystals
CC-2, 29 wt%
spray-dried lactose, 40 wt% PEO WSRN-10 (100,000 daltons), and 1 wt% magnesium
stearate. The tablets were prepared by first blending the coated crystals,
lactose, and PEO in
a twin-shell blender for 20 minutes, milling using a Fitzpatric M5A mill, and
then blending in
the twin-shell blender for an additional 20 minutes. The magnesium stearate
was then added
and the mixture blended again for 5 minutes. The tablets were manufactured
using an F
press using 381 mg of'the mixture using capiet-shaped tooling with dimensions
0.30 inches,
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-42-
by 0.60 inches. The tablet cores were compressed to a hardness of about 13 kp.
The
resulting sustained-release matrix tablet contained a total of 40 mg active
ziprasidone.
Dosage Form DF-7
Dosage Form DF-7 consisted of Dosage Form DF-6 that had been coated with an
enteric coating. The coating solution consisted of 41.7 wt% Eudragit L30-D55
and 2.5 wt%
triethylcitrate in 55.8 wt% water. Coatings were applied in an LDCS-20 pan
coater. The
coating weight was 10 wt% of the uncoated core weight. The resulting sustained-
release
matrix tablet contained at total of 40 mg active ziprasidone.
Dosage Form DF-8
A bilayer osmotic dosage form containing coated crystals of ziprasidone
tosylate (CC-
3) was prepared using the following procedures.
Preparation of the Drug-Containing Composition
To form the drug-containing composition, the following materials were blended:
25.0
wt% CC-3, 74.0 wt% PEO WSR N80, and 1.0 wt% magnesium stearate. The drug-
containing
composition ingredients were first combined without magnesium stearate,
blended for 20
minutes in a Turbula mixer, passed through a 20 mesh sieve, and blended again
for 20
minutes. One half of the magnesium stearate was then added to the blend and
the mixture.
blended for an additional 4 minutes. Next, the ingredients were compressed to
4 kP using an
F press with '/h-inch standard round concave tooling, ground using a mortar
and pestle, and
passed through a 20 mesh sieve. Finally, the remaining magnesium stearate
was,added, and
the ingredients were blended again for 4 minutes.
Preparation of the Water-Swellable Composition
To form the water-swellable composition, the following materials were blended:
65.0
wt% PEO WSR coagulant,. 34.3 wt% sodium chloride, 0.5 wt% magnesium stearate,
and 0.2
wt% Blue Lake #2. All ingredients except magnesium stearate were combined and
blended
for 20 minutes, passed through a 20 mesh sieve, and blended again for 20
minutes. The
magnesium stearate was added, and the mixture was blended for 4 minutes.
Preparation of Tablet Cores
Bilayer tablet cores were manufactured using an F press combining 453 mg of
the
drug-containing composition and 227 mg of the water-swellable composition with
7/16-inch
SRC tooling. The tablet cores were compressed to a hardness of about 11 kp.
The resulting
bi-layer tablet core had a total, weight of 680 mg and contained a total of 40
mg active
ziprasidone.
Application of the Coating
Coatings for the tablet cores were applied in a Vector LDCS-20 pan coater. The
coating solution contained CA 398-10, PEG 3350, water, and acetone in a weight
ratio of
4.25/0.75/2.5/92.5 (wt%). The flow rate of the inlet heated drying gas of the
pan coater was
CA 02577852 2007-02-20
WO 2006/024944 PCT/IB2005/002704
-43-
set at 40 ft3/min with the outlet temperature set at 25 C. Nitrogen at 20 psi
was used to
atomize the coating solution from the spray nozzle, with a nozzle-to-bed
distance of 2 inches.
The pan rotation was set to 20 rpm. The so-coated tablets were dried 16 hr at
40 C in a tray-
drier. The final dry coating weight amounted to about 10.35 wt% of the tablet
core. One
900 m diameter hole was laser-drilled in the coating on the drug-containing
composition side
of each of the tablets to provide one delivery port per tablet.
Dosage Form DF-9
Dosage Form DF-9 consisted of a single-layer osmotic tablet that provided
sustained
release of ziprasidone. The dosage form contained coated crystals of
ziprasidone
hydrochloride monohydrate (CC-2). The tablet core consisted of 26.5 wt% of the
coated
crystals CC-2, 60.0 wt% sorbitol, 8.0 wt% hydroxy ethyl cellulose (Natrosol
250HX), 1.5 wt%
sodium lauryl sulfate (SLS), 3.0 wt% hydroxypropyl cellulose (Klucel EXF), and
1.0 wt%
magnesium stearate. To form the tablet core, all of the ingredients except for
the magnesium
stearate were blended in a twin-shell blender for 15 minutes. The blend was
then passed
through a Fitzmill M5A equipped with a 0.031-inch Conidur rasping screen at
200 rpm. The
blend was then returned to the twin-shell blender and blended an additional 15
minutes. One
half of the magnesium stearate was then added to the blend and the mixture
blended for an
additional 3 minutes. The dry blend was then roller compacted using a Vector
Feund TF Mini
roller compactor with "S" rolls, using a roll pressure of 390 to 400 psi, a
roller speed of 3-4
rpm, and a screw speed of 4-6 rpm. The roller compacted ribbons were then
milled using the
Fitzmill M5A. The milled material was then returned to a twin-shell blender
and blended for
10 minutes, at which time the remaining magnesium stearate was added and the
mixture
blended for an additional 3 minutes. The tablet cores were then formed using a
Killian T100
tablet press using 0.2838-inch by 0.5678-inch rnodified oval tooling. A
coating was applied to
the tablet core using the procedures outlined for DF-1, except that the
coating solution
contained CA 398-10, PEG 3350, water, and acetone in a weight ratio of
4.5/1.5/5/89 (wt%),
and amounted to 7.5 wt% of the core weight. Each tablet of DF-9 contained 40
mgA of
ziprasidone.
The terms and expressions which have been employed in the foregoing
specification
are used therein as terms of description and not of limitation, and there is
no intention, in the
use of such terms and expressions, of excluding equivalents of the features
shown and
described or portions thereof, it being recognized that the scope of the
invention is defined
and limited only by the claims which follow.
